1
|
Roug A, Meyer L, Netshitavhadulu L, Leiberich M, Buss P. Ketamine-butorphanol-medetomidine for the immobilisation of free-living hyenas (Crocuta crocuta). J S Afr Vet Assoc 2024; 95:35-42. [PMID: 38533813 DOI: 10.36303/jsava.572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/28/2024] Open
Abstract
Free-ranging spotted hyenas (Crocuta crocuta) are immobilised for a variety of purposes, including wildlife-human conflict mitigation, research, and veterinary treatment. Combinations of tiletamine-zolazepam (Zoletil) and medetomidine are commonly used for immobilisation of hyenas, however, recovery times are long. In this descriptive study, a total of 20 adult or subadult free-ranging hyenas were immobilised near Skukuza in the Kruger National Park using ketamine, butorphanol, and medetomidine. The goal of the study was to evaluate a suitable dose and measure cardiorespiratory effects of this combination. The quality of induction and recovery were scored using an established scoring system from 1 (excellent) to (poor). Twelve of the 20 hyenas were given an induction score of 1 (excellent), five an induction score of 2 (good), and three an induction score of 3 (fair). Of the animals with induction score = 1, the mean drug dose was 1.17 mg/kg ketamine, 0.25 mg/kg butorphanol and 0.03 mg/kg medetomidine, and the mean induction time and time to handling 6:25 minutes and 9:46 minutes respectively. The mean recovery time (from reversal to standing) was 10:16 min, which is shorter than what has been reported for tiletaminezolazepam- based combinations in hyenas. Most hyenas were bradycardic (< 40 beats per minute) and the mean PaO2 69.5 mmHg. Three hyenas, one with induction score = 2, and two with induction scores = 3 spontaneously recovered at 33, 44 and 56 minutes post approach respectively. Regardless of induction time, all hyenas reached a level of surgical anaesthesia while immobilised. Overall, ketamine-butorphanol-medetomidine (KBM) was effective in immobilising hyenas but induction times varied, and animals were bradycardic during immobilisation.
Collapse
Affiliation(s)
- A Roug
- Department of Production Animal Studies and Centre for Veterinary Wildlife Research, Faculty of Veterinary Science, University of Pretoria, South Africa
| | - L Meyer
- Department of Paraclinical Sciences and Centre for Veterinary Wildlife Research, Faculty of Veterinary Science, University of Pretoria, South Africa
| | - L Netshitavhadulu
- Wildlife Veterinary Services, Kruger National Park, South African National Parks, South Africa
| | - M Leiberich
- Department of Paraclinical Sciences and Centre for Veterinary Wildlife Research, Faculty of Veterinary Science, University of Pretoria, South Africa
| | - P Buss
- Department of Production Animal Studies and Centre for Veterinary Wildlife Research, Faculty of Veterinary Science, University of Pretoria, South Africa
- Wildlife Veterinary Services, Kruger National Park, South African National Parks, South Africa
| |
Collapse
|
2
|
Flick K, Smeets R, Gosau M, Meyer L, Hanning U, Kyselyova AA, Scheifele C, Höhmann B, Henningsen A. Assessment of the intrasinusidal volume before and after maxillary sinus augmentation using mri - a pilot study of eight patients. BMC Oral Health 2024; 24:142. [PMID: 38287339 PMCID: PMC10823631 DOI: 10.1186/s12903-024-03858-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2023] [Accepted: 01/04/2024] [Indexed: 01/31/2024] Open
Abstract
PURPOSE The purpose of this study was to evaluate the suitability, accuracy, and reliability of a non-invasive 3-Tesla magnetic resonance imaging technique (3 T-MRI) for the visualization of maxillary sinus grafts in comparison to conventional, X-ray-based, established standard imaging techniques. METHODS A total of eight patients with alveolar bone atrophy who required surgical sinus floor augmentation in the course of dental implantation were included in this pilot study. Alongside pre-operative cone-beam computed tomography (CBCT), 3 T-MRI was performed before and 6 months after sinus floor augmentation. Two investigators measured the maxillary sinus volume preoperatively and after bone augmentation. RESULTS In all cases, MRI demonstrated accurately the volumes of the maxillary sinus grafts. Following surgery, the bony structures suitable for an implant placement increased at an average of 4.89 cm3, corresponding with the decrease of the intrasinusidal volumes. In general, interexaminer discrepancies were low and without statistical significance. CONCLUSION In this preliminary study, we could demonstrate the feasibility of MRI bone volume measurement as a radiation-free alternative with comparable accuracy to CT/CBCT before procedures like sinus floor augmentation. Nevertheless, costs and artifacts, also present in MRI, have to be taken into account. Larger studies will be necessary to justify the practicability of MRI bone volume evaluation.
Collapse
Affiliation(s)
- K Flick
- Department of Oral and Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
- Division of "Regenerative Orofacial Medicine", Department of Oral and Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
| | - R Smeets
- Department of Oral and Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany
- Division of "Regenerative Orofacial Medicine", Department of Oral and Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - M Gosau
- Department of Oral and Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany
| | - L Meyer
- Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - U Hanning
- Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - A A Kyselyova
- Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - C Scheifele
- Dental Radiology Unit, Center for Dental and Oral Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - B Höhmann
- Department of Preventive and Restorative Dentistry, Center for Dental and Oral Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - A Henningsen
- Department of Oral and Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany
- Division of "Regenerative Orofacial Medicine", Department of Oral and Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
3
|
Miguel V, Reimer KC, Galyga AK, Jansen J, Möllmann J, Meyer L, Schneider RK, Kramann R. Protocol to analyze bioenergetics in single human induced-pluripotent-stem-cell-derived kidney organoids using Seahorse XF96. STAR Protoc 2023; 4:101999. [PMID: 36607813 PMCID: PMC9850189 DOI: 10.1016/j.xpro.2022.101999] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2022] [Revised: 11/28/2022] [Accepted: 12/16/2022] [Indexed: 01/07/2023] Open
Abstract
Metabolic derangement is a key culprit in kidney pathophysiology. Organoids have emerged as a promising in vitro tool for kidney research. Here, we present a fine-tuned protocol to analyze bioenergetics in single human induced-pluripotent-stem-cell (iPSC)-derived kidney organoids using Seahorse XF96. We describe the generation of self-organized three-dimensional kidney organoids, followed by preparation of organoids for Seahorse XF96 analysis. We then detail how to carry out stress tests to determine mitochondrial and glycolytic rates in single kidney organoids.
Collapse
Affiliation(s)
- Verónica Miguel
- Institute of Experimental Medicine and Systems Biology, RWTH Aachen University Hospital, Aachen, Germany.
| | - Katharina Charlotte Reimer
- Institute of Experimental Medicine and Systems Biology, RWTH Aachen University Hospital, Aachen, Germany; Institute for Biomedical Technologies, Department of Cell Biology, RWTH Aachen University, Aachen, Germany; Department of Nephrology and Hypertensive Disorders, Rheumatology, and Clinical Immunology (Medical Clinic II), University Hospital RWTH Aachen, Aachen, Germany
| | - Anna Katharina Galyga
- Institute for Biomedical Technologies, Department of Cell Biology, RWTH Aachen University, Aachen, Germany
| | - Jitske Jansen
- Institute of Experimental Medicine and Systems Biology, RWTH Aachen University Hospital, Aachen, Germany; Department of Pathology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Julia Möllmann
- Department of Internal Medicine I, Cardiology, University Hospital RWTH Aachen, Aachen, Germany
| | - Luisa Meyer
- Department of Internal Medicine I, Cardiology, University Hospital RWTH Aachen, Aachen, Germany
| | - Rebekka K Schneider
- Institute for Biomedical Technologies, Department of Cell Biology, RWTH Aachen University, Aachen, Germany
| | - Rafael Kramann
- Institute of Experimental Medicine and Systems Biology, RWTH Aachen University Hospital, Aachen, Germany; Department of Nephrology and Hypertensive Disorders, Rheumatology, and Clinical Immunology (Medical Clinic II), University Hospital RWTH Aachen, Aachen, Germany.
| |
Collapse
|
4
|
Angloher G, Banik S, Bartolot D, Benato G, Bento A, Bertolini A, Breier R, Bucci C, Burkhart J, Canonica L, D’Addabbo A, Di Lorenzo S, Einfalt L, Erb A, Feilitzsch FV, Iachellini NF, Fichtinger S, Fuchs D, Fuss A, Garai A, Ghete VM, Gerster S, Gorla P, Guillaumon PV, Gupta S, Hauff D, Ješkovský M, Jochum J, Kaznacheeva M, Kinast A, Kluck H, Kraus H, Lackner M, Langenkämper A, Mancuso M, Marini L, Meyer L, Mokina V, Nilima A, Olmi M, Ortmann T, Pagliarone C, Pattavina L, Petricca F, Potzel W, Povinec P, Pröbst F, Pucci F, Reindl F, Rizvanovic D, Rothe J, Schäffner K, Schieck J, Schmiedmayer D, Schönert S, Schwertner C, Stahlberg M, Stodolsky L, Strandhagen C, Strauss R, Usherov I, Wagner F, Willers M, Zema V, Waltenberger W. Towards an automated data cleaning with deep learning in CRESST. Eur Phys J Plus 2023; 138:100. [PMID: 36741916 PMCID: PMC9886615 DOI: 10.1140/epjp/s13360-023-03674-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Accepted: 01/02/2023] [Indexed: 06/18/2023]
Abstract
The CRESST experiment employs cryogenic calorimeters for the sensitive measurement of nuclear recoils induced by dark matter particles. The recorded signals need to undergo a careful cleaning process to avoid wrongly reconstructed recoil energies caused by pile-up and read-out artefacts. We frame this process as a time series classification task and propose to automate it with neural networks. With a data set of over one million labeled records from 68 detectors, recorded between 2013 and 2019 by CRESST, we test the capability of four commonly used neural network architectures to learn the data cleaning task. Our best performing model achieves a balanced accuracy of 0.932 on our test set. We show on an exemplary detector that about half of the wrongly predicted events are in fact wrongly labeled events, and a large share of the remaining ones have a context-dependent ground truth. We furthermore evaluate the recall and selectivity of our classifiers with simulated data. The results confirm that the trained classifiers are well suited for the data cleaning task.
Collapse
Affiliation(s)
- G. Angloher
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - S. Banik
- Institut für Hochenergiephysik der Österreichischen Akademie der Wissenschaften, A-1050 Wien, Austria
- Atominstitut, Technische Universität Wien, A-1020 Wien, Austria
| | - D. Bartolot
- Institut für Hochenergiephysik der Österreichischen Akademie der Wissenschaften, A-1050 Wien, Austria
| | - G. Benato
- INFN, Laboratori Nazionali del Gran Sasso, I-67100 Assergi, Italy
| | - A. Bento
- Max-Planck-Institut für Physik, D-80805 München, Germany
- LIBPhys-UC, Departamento de Fisica, Universidade de Coimbra, P3004 516 Coimbra, Portugal
| | - A. Bertolini
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - R. Breier
- Faculty of Mathematics, Physics and Informatics, Comenius University, 84248 Bratislava, Slovakia
| | - C. Bucci
- INFN, Laboratori Nazionali del Gran Sasso, I-67100 Assergi, Italy
| | - J. Burkhart
- Institut für Hochenergiephysik der Österreichischen Akademie der Wissenschaften, A-1050 Wien, Austria
| | - L. Canonica
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - A. D’Addabbo
- INFN, Laboratori Nazionali del Gran Sasso, I-67100 Assergi, Italy
| | - S. Di Lorenzo
- INFN, Laboratori Nazionali del Gran Sasso, I-67100 Assergi, Italy
| | - L. Einfalt
- Institut für Hochenergiephysik der Österreichischen Akademie der Wissenschaften, A-1050 Wien, Austria
- Atominstitut, Technische Universität Wien, A-1020 Wien, Austria
| | - A. Erb
- Physik-Department, Technische Universität München, D-85747 Garching, Germany
- Walther-Meißner-Institut für Tieftemperaturforschung, D-85748 Garching, Germany
| | - F. v. Feilitzsch
- Physik-Department, Technische Universität München, D-85747 Garching, Germany
| | | | - S. Fichtinger
- Institut für Hochenergiephysik der Österreichischen Akademie der Wissenschaften, A-1050 Wien, Austria
| | - D. Fuchs
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - A. Fuss
- Institut für Hochenergiephysik der Österreichischen Akademie der Wissenschaften, A-1050 Wien, Austria
- Atominstitut, Technische Universität Wien, A-1020 Wien, Austria
| | - A. Garai
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - V. M. Ghete
- Institut für Hochenergiephysik der Österreichischen Akademie der Wissenschaften, A-1050 Wien, Austria
| | - S. Gerster
- Eberhard-Karls-Universität Tübingen, D-72076 Tübingen, Germany
| | - P. Gorla
- INFN, Laboratori Nazionali del Gran Sasso, I-67100 Assergi, Italy
| | - P. V. Guillaumon
- INFN, Laboratori Nazionali del Gran Sasso, I-67100 Assergi, Italy
| | - S. Gupta
- Institut für Hochenergiephysik der Österreichischen Akademie der Wissenschaften, A-1050 Wien, Austria
| | - D. Hauff
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - M. Ješkovský
- Faculty of Mathematics, Physics and Informatics, Comenius University, 84248 Bratislava, Slovakia
| | - J. Jochum
- Eberhard-Karls-Universität Tübingen, D-72076 Tübingen, Germany
| | - M. Kaznacheeva
- Physik-Department, Technische Universität München, D-85747 Garching, Germany
| | - A. Kinast
- Physik-Department, Technische Universität München, D-85747 Garching, Germany
| | - H. Kluck
- Institut für Hochenergiephysik der Österreichischen Akademie der Wissenschaften, A-1050 Wien, Austria
| | - H. Kraus
- Department of Physics, University of Oxford, Oxford, OX1 3RH UK
| | - M. Lackner
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - A. Langenkämper
- Max-Planck-Institut für Physik, D-80805 München, Germany
- Physik-Department, Technische Universität München, D-85747 Garching, Germany
| | - M. Mancuso
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - L. Marini
- INFN, Laboratori Nazionali del Gran Sasso, I-67100 Assergi, Italy
- GSSI-Gran Sasso Science Institute, I-67100 L’Aquila, Italy
| | - L. Meyer
- Eberhard-Karls-Universität Tübingen, D-72076 Tübingen, Germany
| | - V. Mokina
- Institut für Hochenergiephysik der Österreichischen Akademie der Wissenschaften, A-1050 Wien, Austria
| | - A. Nilima
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - M. Olmi
- INFN, Laboratori Nazionali del Gran Sasso, I-67100 Assergi, Italy
| | - T. Ortmann
- Physik-Department, Technische Universität München, D-85747 Garching, Germany
| | - C. Pagliarone
- INFN, Laboratori Nazionali del Gran Sasso, I-67100 Assergi, Italy
- Dipartimento di Ingegneria Civile e Meccanica, Universitá degli Studi di Cassino e del Lazio Meridionale, I-03043 Cassino, Italy
| | - L. Pattavina
- INFN, Laboratori Nazionali del Gran Sasso, I-67100 Assergi, Italy
- Physik-Department, Technische Universität München, D-85747 Garching, Germany
| | - F. Petricca
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - W. Potzel
- Physik-Department, Technische Universität München, D-85747 Garching, Germany
| | - P. Povinec
- Faculty of Mathematics, Physics and Informatics, Comenius University, 84248 Bratislava, Slovakia
| | - F. Pröbst
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - F. Pucci
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - F. Reindl
- Institut für Hochenergiephysik der Österreichischen Akademie der Wissenschaften, A-1050 Wien, Austria
- Atominstitut, Technische Universität Wien, A-1020 Wien, Austria
| | - D. Rizvanovic
- Institut für Hochenergiephysik der Österreichischen Akademie der Wissenschaften, A-1050 Wien, Austria
| | - J. Rothe
- Physik-Department, Technische Universität München, D-85747 Garching, Germany
| | - K. Schäffner
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - J. Schieck
- Institut für Hochenergiephysik der Österreichischen Akademie der Wissenschaften, A-1050 Wien, Austria
- Atominstitut, Technische Universität Wien, A-1020 Wien, Austria
| | - D. Schmiedmayer
- Institut für Hochenergiephysik der Österreichischen Akademie der Wissenschaften, A-1050 Wien, Austria
- Atominstitut, Technische Universität Wien, A-1020 Wien, Austria
| | - S. Schönert
- Physik-Department, Technische Universität München, D-85747 Garching, Germany
| | - C. Schwertner
- Institut für Hochenergiephysik der Österreichischen Akademie der Wissenschaften, A-1050 Wien, Austria
- Atominstitut, Technische Universität Wien, A-1020 Wien, Austria
| | - M. Stahlberg
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - L. Stodolsky
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - C. Strandhagen
- Eberhard-Karls-Universität Tübingen, D-72076 Tübingen, Germany
| | - R. Strauss
- Physik-Department, Technische Universität München, D-85747 Garching, Germany
| | - I. Usherov
- Eberhard-Karls-Universität Tübingen, D-72076 Tübingen, Germany
| | - F. Wagner
- Institut für Hochenergiephysik der Österreichischen Akademie der Wissenschaften, A-1050 Wien, Austria
| | - M. Willers
- Physik-Department, Technische Universität München, D-85747 Garching, Germany
| | - V. Zema
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - W. Waltenberger
- Institut für Hochenergiephysik der Österreichischen Akademie der Wissenschaften, A-1050 Wien, Austria
| | | |
Collapse
|
5
|
Seo A, Lakomy D, Colbert L, Jhingran A, Joyner M, Klopp A, Meyer L, Eifel P, Lin L. Impact of Para-Aortic Lymph Node Count on Survival in Patients with Cervical Cancer and Para-Aortic Lymph Node Involvement Treated with Definitive Radiation Therapy. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
6
|
Meyer L, Roy RP, Huang B, Kimura S, Polonen P, Delgado-Martin C, Vincent T, Ryan T, Wood B, Liu Y, Zhang J, Mullighan C, Horton T, Loh M, Devidas M, Raetz E, Hayashi R, Winter S, Dunsmore K, Hunger S, Teachey D, Hermiston M, Olshen AB. A TARGETED GENE EXPRESSION CLASSIFIER IDENTIFIES PEDIATRIC T-ALL PATIENTS AT HIGH RISK FOR END INDUCTION MINIMAL RESIDUAL DISEASE POSITIVITY. Leuk Res 2022. [DOI: 10.1016/s0145-2126(22)00243-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
7
|
Marcellin F, Brégigeon-Ronot S, Ramier C, Protopopescu C, Gilbert C, Di Beo V, Duvivier C, Bureau-Stoltmann M, Rosenthal E, Wittkop L, Salmon-Céron D, Carrieri P, Sogni P, Barré T, Salmon D, Wittkop L, Sogni P, Esterle L, Trimoulet P, Izopet J, Serfaty L, Paradis V, Spire B, Carrieri P, Valantin M, Pialoux G, Chas J, Zaegel-Faucher O, Barange K, Naqvi A, Rosenthal E, Bicart-See A, Bouchaud O, Gervais A, Lascoux-Combe C, Goujard C, Lacombe K, Duvivier C, Neau D, Morlat P, Bani-Sadr F, Meyer L, Boufassa F, Autran B, Roque A, Solas C, Fontaine H, Costagliola D, Piroth L, Simon A, Zucman D, Boué F, Miailhes P, Billaud E, Aumaître H, Rey D, Peytavin G, Petrov-Sanchez V, Levier A, Salmon D, Usubillaga R, Sogni P, Terris B, Tremeaux P, Katlama C, Valantin M, Stitou H, Simon A, Cacoub P, Nafissa S, Benhamou Y, Charlotte F, Fourati S, Poizot-Martin I, Zaegel O, Laroche H, Tamalet C, Pialoux G, Chas J, Callard P, Bendjaballah F, Amiel C, Le Pendeven C, Marchou B, Alric L, Barange K, Metivier S, Selves J, Larroquette F, Rosenthal E, Naqvi A, Rio V, Haudebourg J, Saint-Paul M, De Monte A, Giordanengo V, Partouche C, Bouchaud O, Martin A, Ziol M, Baazia Y, Iwaka-Bande V, Gerber A, Uzan M, Bicart-See A, Garipuy D, Ferro-Collados M, Selves J, Nicot F, Gervais A, Yazdanpanah Y, Adle-Biassette H, Alexandre G, Peytavin G, Lascoux-Combe C, Molina J, Bertheau P, Chaix M, Delaugerre C, Maylin S, Lacombe K, Bottero J, Krause J, Girard P, Wendum D, Cervera P, Adam J, Viala C, Vittecocq D, Goujard C, Quertainmont Y, Teicher E, Pallier C, Lortholary O, Duvivier C, Rouzaud C, Lourenco J, Touam F, Louisin C, Avettand-Fenoel V, Gardiennet E, Mélard A, Neau D, Ochoa A, Blanchard E, Castet-Lafarie S, Cazanave C, Malvy D, Dupon M, Dutronc H, Dauchy F, Lacaze-Buzy L, Desclaux A, Bioulac-Sage P, Trimoulet P, Reigadas S, Morlat P, Lacoste D, Bonnet F, Bernard N, Hessamfar M, Paccalin J, Martell C, Pertusa M, Vandenhende M, Mercié P, Malvy D, Pistone T, Receveur M, Méchain M, Duffau P, Rivoisy C, Faure I, Caldato S, Bioulac-Sage P, Trimoulet P, Reigadas S, Bellecave P, Tumiotto C, Pellegrin J, Viallard J, Lazzaro E, Greib C, Bioulac-Sage P, Trimoulet P, Reigadas S, Zucman D, Majerholc C, Brollo M, Farfour E, Boué F, Polo Devoto J, Kansau I, Chambrin V, Pignon C, Berroukeche L, Fior R, Martinez V, Abgrall S, Favier M, Deback C, Lévy Y, Dominguez S, Lelièvre J, Lascaux A, Melica G, Billaud E, Raffi F, Allavena C, Reliquet V, Boutoille D, Biron C, Lefebvre M, Hall N, Bouchez S, Rodallec A, Le Guen L, Hemon C, Miailhes P, Peyramond D, Chidiac C, Ader F, Biron F, Boibieux A, Cotte L, Ferry T, Perpoint T, Koffi J, Zoulim F, Bailly F, Lack P, Maynard M, Radenne S, Amiri M, Valour F, Koffi J, Zoulim F, Bailly F, Lack P, Maynard M, Radenne S, Augustin-Normand C, Scholtes C, Le-Thi T, Piroth L, Chavanet P, Duong Van Huyen M, Buisson M, Waldner-Combernoux A, Mahy S, Salmon Rousseau A, Martins C, Aumaître H, Galim S, Bani-Sadr F, Lambert D, Nguyen Y, Berger J, Hentzien M, Brodard V, Rey D, Partisani M, Batard M, Cheneau C, Priester M, Bernard-Henry C, de Mautort E, Fischer P, Gantner et S Fafi-Kremer P, Roustant F, Platterier P, Kmiec I, Traore L, Lepuil S, Parlier S, Sicart-Payssan V, Bedel E, Anriamiandrisoa S, Pomes C, Touam F, Louisin C, Mole M, Bolliot C, Catalan P, Mebarki M, Adda-Lievin A, Thilbaut P, Ousidhoum Y, Makhoukhi F, Braik O, Bayoud R, Gatey C, Pietri M, Le Baut V, Ben Rayana R, Bornarel D, Chesnel C, Beniken D, Pauchard M, Akel S, Caldato S, Lions C, Ivanova A, Ritleg AS, Debreux C, Chalal L, J.Zelie, Hue H, Soria A, Cavellec M, Breau S, Joulie A, Fisher P, Gohier S, Croisier-Bertin D, Ogoudjobi S, Brochier C, Thoirain-Galvan V, Le Cam M, Carrieri P, Chalouni M, Conte V, Dequae-Merchadou L, Desvallées M, Esterle L, Gilbert C, Gillet S, Guillochon Q, Khan C, Knight R, Marcellin F, Michel L, Mora M, Protopopescu C, Roux P, Spire B, Barré T, Ramier C, Sow A, Lions C, Di Beo V, Bureau M, Wittkop L. Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH). JHEP Rep 2022; 5:100614. [DOI: 10.1016/j.jhepr.2022.100614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/21/2022] [Revised: 10/06/2022] [Accepted: 10/07/2022] [Indexed: 11/06/2022] Open
|
8
|
Barré T, Mercié P, Lions C, Miailhes P, Zucman D, Aumaître H, Esterle L, Sogni P, Carrieri P, Salmon-Céron D, Marcellin F, Salmon D, Wittkop L, Sogni P, Esterle L, Trimoulet P, Izopet J, Serfaty L, Paradis V, Spire B, Carrieri P, Valantin MA, Pialoux G, Chas J, Poizot-Martin I, Barange K, Naqvi A, Rosenthal E, Bicart-See A, Bouchaud O, Gervais A, Lascoux-Combe C, Goujard C, Lacombe K, Duvivier C, Neau D, Morlat P, Bani-Sadr F, Meyer L, Boufassa F, Autran B, Roque AM, Solas C, Fontaine H, Costagliola D, Piroth L, Simon A, Zucman D, Boué F, Miailhes P, Billaud E, Aumaître H, Rey D, Peytavin G, Petrov-Sanchez V, Levier A, Usubillaga R, Terris B, Tremeaux P, Katlama C, Valantin MA, Stitou H, Cacoub P, Nafissa S, Benhamou Y, Charlotte F, Fourati S, Zaegel O, Laroche H, Tamalet C, Callard P, Bendjaballah F, Le Pendeven C, Marchou B, Alric L, Metivier S, Selves J, Larroquette F, Rio V, Haudebourg J, Saint-Paul MC, De Monte A, Giordanengo V, Partouche C, Martin A, Ziol M, Baazia Y, Iwaka-Bande V, Gerber A, Uzan M, Garipuy D, Ferro-Collados MJ, Nicot F, Yazdanpanah Y, Adle-Biassette H, Alexandre G, Molina JM, Bertheau P, Chaix ML, Delaugerre C, Maylin S, Bottero J, Krause J, Girard PM, Wendum D, Cervera P, Adam J, Viala C, Vittecocq D, Quertainmont Y, Teicher E, Pallier C, Lortholary O, Rouzaud C, Lourenco J, Touam F, Louisin C, Avettand-Fenoel V, Gardiennet E, Mélard A, Ochoa A, Blanchard E, Castet-Lafarie S, Cazanave C, Malvy D, Dupon M, Dutronc H, Dauchy F, Lacaze-Buzy L, Desclaux A, Bioulac-Sage P, Reigadas S, Lacoste D, Bonnet F, Bernard N, Hessamfar M, J, Paccalin F, Martell C, Pertusa MC, Vandenhende M, Mercié P, Pistone T, Receveur MC, Méchain M, Duffau P, Rivoisy C, Faure I, Caldato S, Bellecave P, Tumiotto C, Pellegrin JL, Viallard JF, Lazzaro E, Greib C, Majerholc C, Brollo M, Farfour E, Devoto JP, Kansau I, Chambrin V, Pignon C, Berroukeche L, Fior R, Martinez V, Abgrall S, Favier M, Deback C, Lévy Y, Dominguez S, Lelièvre JD, Lascaux AS, Melica G, Raffi F, Allavena C, Reliquet V, Boutoille D, Biron C, Lefebvre M, Hall N, Bouchez S, Rodallec A, Le Guen L, Hemon C, Peyramond D, Chidiac C, Ader F, Biron F, Boibieux A, Cotte L, Ferry T, Perpoint T, Koffi J, Zoulim F, Bailly F, Lack P, Maynard M, Radenne S, Amiri M, Valour F, Augustin-Normand C, Scholtes C, Le-Thi TT, Van Huyen PCMD, Buisson M, Waldner-Combernoux A, Mahy S, Rousseau AS, Martins C, Galim S, Lambert D, Nguyen Y, Berger JL, Hentzien M, Brodard V, Partisani M, Batard ML, Cheneau C, Priester M, Bernard-Henry C, de Mautort E, Fischer P, Gantner P, Fafi-Kremer S, Roustant F, Platterier P, Kmiec I, Traore L, Lepuil S, Parlier S, Sicart-Payssan V, Bedel E, Anriamiandrisoa S, Pomes C, Mole M, Bolliot C, Catalan P, Mebarki M, Adda-Lievin A, Thilbaut P, Ousidhoum Y, Makhoukhi FZ, Braik O, Bayoud R, Gatey C, Pietri MP, Le Baut V, Rayana RB, Bornarel D, Chesnel C, Beniken D, Pauchard M, Akel S, Lions C, Ivanova A, Ritleg AS, Debreux C, Chalal L, Zelie J, Hue H, Soria A, Cavellec M, Breau S, Joulie A, Fisher P, Gohier S, Croisier-Bertin D, Ogoudjobi S, Brochier C, Thoirain-Galvan V, Le Cam M, Chalouni M, Conte V, Dequae-Merchadou L, Desvallees M, Gilbert C, Gillet S, Knight R, Lemboub T, Marcellin F, Michel L, Mora M, Protopopescu C, Roux P, Tezkratt S, Barré T, Rojas TR, Baudoin M, Di Beo MSV, Nishimwe M. HCV cure: an appropriate moment to reduce cannabis use in people living with HIV? (ANRS CO13 HEPAVIH data). AIDS Res Ther 2022; 19:15. [PMID: 35292069 PMCID: PMC8922772 DOI: 10.1186/s12981-022-00440-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2021] [Accepted: 03/06/2022] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Thanks to direct-acting antivirals, hepatitis C virus (HCV) infection can be cured, with similar rates in HCV-infected and HIV-HCV co-infected patients. HCV cure is likely to foster behavioral changes in psychoactive substance use, which is highly prevalent in people living with HIV (PLWH). Cannabis is one substance that is very commonly used by PLWH, sometimes for therapeutic purposes. We aimed to identify correlates of cannabis use reduction following HCV cure in HIV-HCV co-infected cannabis users and to characterize persons who reduced their use. METHODS We used data collected on HCV-cured cannabis users in a cross-sectional survey nested in the ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients, to perform logistic regression, with post-HCV cure cannabis reduction as the outcome, and socio-behavioral characteristics as potential correlates. We also characterized the study sample by comparing post-cure substance use behaviors between those who reduced their cannabis use and those who did not. RESULTS Among 140 HIV-infected cannabis users, 50 and 5 had reduced and increased their use, respectively, while 85 had not changed their use since HCV cure. Cannabis use reduction was significantly associated with tobacco use reduction, a decrease in fatigue level, paying more attention to one's dietary habits since HCV cure, and pre-HCV cure alcohol abstinence (p = 0.063 for alcohol use reduction). CONCLUSIONS Among PLWH using cannabis, post-HCV cure cannabis reduction was associated with tobacco use reduction, improved well-being, and adoption of healthy behaviors. The management of addictive behaviors should therefore be encouraged during HCV treatment.
Collapse
|
9
|
Beaumont AL, Vignes D, Sterpu R, Bussone G, Kansau I, Pignon C, Ben Ismail R, Favier M, Molitor JL, Braham D, Fior R, Roy S, Mion M, Meyer L, Andronikof M, Damoisel C, Chagué P, Aurégan JC, Bourgeois-Nicolaos N, Guillet-Caruba C, Téglas JP, Abgrall S. Factors associated with hospital admission and adverse outcome for COVID-19: role of social factors and medical care. Infect Dis Now 2022; 52:130-137. [PMID: 35172217 PMCID: PMC8841005 DOI: 10.1016/j.idnow.2022.02.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2021] [Revised: 11/10/2021] [Accepted: 02/01/2022] [Indexed: 12/12/2022]
Abstract
Background Beyond sex, age, and various comorbidities, geographical origin and socioeconomic deprivation are associated with Coronavirus Disease (COVID-19) morbidity and mortality in the general population. We aimed to assess factors associated with severe forms of COVID-19 after a hospital emergency department visit, focusing on socioeconomic factors. Methods Patients with laboratory-confirmed COVID-19 attending the emergency department of Béclère Hospital (France) in March–April 2020 were included. Postal addresses were used to obtain two geographical deprivation indices at the neighborhood level. Factors associated with hospitalization and factors associated with adverse outcomes, i.e. mechanical ventilation or death, were studied using logistic and Cox analyses, respectively. Results Among 399 included patients, 321 were hospitalized. Neither geographical origin nor socioeconomic deprivation was associated with any of the outcomes. Being male, older, overweight or obese, diabetic, or having a neuropsychiatric disorder were independent risk factors for hospitalization. Among 296 patients hospitalized at Béclère Hospital, 91 experienced an adverse outcome. Older age, being overweight or obese, desaturation and extent of chest CT scan lesions > 25% at admission (aHR: 2.2 [95% CI: 1.3–3.5]) and higher peak CRP levels and acute kidney failure (aHR: 2.0 [1.2–3.3]) during follow-up were independently associated with adverse outcomes, whereas treatment with hydrocortisone reduced the risk of mechanical ventilation or death by half (aHR: 0.5 [0.3–0.8]). Conclusion No association between geographical origin or socioeconomic deprivation and the occurrence of a severe form of COVID-19 was observed in our population after arrival to the emergency department. Empirical corticosteroid use with hydrocortisone had a strong protective impact.
Collapse
Affiliation(s)
- A-L Beaumont
- Université Paris-Saclay, UVSQ, INSERM U1018, CESP, Le Kremlin-Bicêtre, France.
| | - D Vignes
- Université Paris-Saclay, UVSQ, INSERM U1018, CESP, Le Kremlin-Bicêtre, France; AP-HP, Hôpital Antoine-Béclère, Service de Médecine Interne, Clamart, France
| | - R Sterpu
- AP-HP, Hôpital Antoine-Béclère, Service de Médecine Interne, Clamart, France
| | - G Bussone
- AP-HP, Hôpital Antoine-Béclère, Service de Médecine Interne, Clamart, France
| | - I Kansau
- AP-HP, Hôpital Antoine-Béclère, Service de Médecine Interne, Clamart, France
| | - C Pignon
- AP-HP, Hôpital Antoine-Béclère, Service de Médecine Interne, Clamart, France
| | - R Ben Ismail
- AP-HP, Hôpital Antoine-Béclère, Service de Médecine Interne, Clamart, France
| | - M Favier
- AP-HP, Hôpital Antoine-Béclère, Service de Médecine Interne, Clamart, France
| | - J-L Molitor
- AP-HP, Hôpital Antoine-Béclère, Service de Médecine Interne, Clamart, France
| | - D Braham
- AP-HP, Hôpital Antoine-Béclère, Service de Médecine Interne, Clamart, France
| | - R Fior
- AP-HP, Hôpital Antoine-Béclère, Service de Médecine Interne, Clamart, France
| | - S Roy
- AP-HP, Hôpital Antoine-Béclère, Pharmacie, Clamart, France
| | - M Mion
- AP-HP, Hôpital Antoine-Béclère, Service de Gériatrie, Clamart, France
| | - L Meyer
- Université Paris-Saclay, UVSQ, INSERM U1018, CESP, Le Kremlin-Bicêtre, France; AP-HP, Hôpital Bicêtre, Service de Santé Publique, Le Kremlin-Bicêtre, France
| | - M Andronikof
- AP-HP, Hôpital Antoine-Béclère, Service d'Accueil des Urgences, Clamart, France
| | - C Damoisel
- AP-HP, Hôpital Antoine-Béclère, Service de Réanimation, Clamart, France
| | - P Chagué
- Université Paris-Saclay, UVSQ, INSERM U1018, CESP, Le Kremlin-Bicêtre, France; AP-HP, Hôpital Antoine-Béclère, Service de Radiologie, Clamart, France
| | - J-C Aurégan
- Université Paris-Saclay, UVSQ, INSERM U1018, CESP, Le Kremlin-Bicêtre, France; AP-HP, Hôpital Antoine-Béclère, Service d'Orthopédie, Clamart, France
| | | | - C Guillet-Caruba
- AP-HP, Hôpital Antoine-Béclère, Service de Bactériologie, Clamart, France
| | - J-P Téglas
- Université Paris-Saclay, UVSQ, INSERM U1018, CESP, Le Kremlin-Bicêtre, France
| | - S Abgrall
- Université Paris-Saclay, UVSQ, INSERM U1018, CESP, Le Kremlin-Bicêtre, France; AP-HP, Hôpital Antoine-Béclère, Service de Médecine Interne, Clamart, France.
| |
Collapse
|
10
|
Gras J, Charreau I, Minier M, Gabassi A, Carette D, Capitant C, Chaix-Baudier M, Meyer L, Molina J, Delaugerre C. Épidémiologie de l’infection HHV8 chez les HSH prenant la PrEP : une sous-étude de l’essai ANRS-IPERGAY. Infect Dis Now 2021. [DOI: 10.1016/j.idnow.2021.06.291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
11
|
Meyer L, Wright J, Downer M, Incerti D, Luhn P, Dolado I, Bastiere-Truchot L, Lin-Liu Y, Chan J. Patterns and adoption of BRCA testing in ovarian cancer in the real world: Observations from Flatiron Health. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.06.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
12
|
Sun C, Molina E, Schneider A, Harrison R, Westin S, Coleman R, Lowenstein L, Volk R, Meyer L. Patient preferences for maintenance therapy versus routine surveillance: Gain in progression-free survival and risks of adverse effects. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.06.155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
13
|
Sun C, Molina E, Schneider A, Harrison R, Westin S, Coleman R, Lowenstein L, Volk R, Meyer L. Patient preferences for side effects and decision-making factors associated with maintenance therapy for ovarian cancer. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.06.154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
14
|
Harrison R, Zhao H, Fu S, Sun C, Westin S, Lu K, Giordano S, Meyer L. Is an endometrial cancer diagnosis a 'teachable moment' leading to weight loss among obese women? A case-control study. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.05.376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
15
|
Villanueva M, Sun C, Schneider A, Molina E, Wang X, Meyer L. Exploring the utility and burden of clinical follow up of threshold alerts generated by patient-reported outcomes in women with recurrent ovarian cancer: A longitudinal study. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.05.474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
16
|
Hillman R, Iniesta M, Suki T, Cain K, Williams L, Wang X, Taylor J, Mena G, Lasala J, Ramirez P, Meyer L. Implementation of a restrictive discharge opioid algorithm after minimally invasive gynecologic surgery: Impact on patient-reported outcomes and refill requests. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.05.470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
17
|
Meyer L, Schneider A, Molina E, Villanueva M, Lowenstein L, Williams L, Sun C. More toxic than treatment? The financial impact of living with ovarian cancer: A qualitative exploration of financial toxicity in women with recurrent ovarian cancer. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.05.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
18
|
Middelhoff J, Ptok H, Will U, Kandulski A, March C, Stroh C, Meyer L, Meyer F. Interventionelle Therapieoptionen der malignen intestinalen Obstruktion. coloproctology 2020. [DOI: 10.1007/s00053-020-00487-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
19
|
Goupil de Bouillé J, Ghislain M, Teglas J, Boufassa F, Vigouroux C, Goujard C, Bouchaud O, Salmon D, Meyer L, Abgrall S. Facteurs de risques associés à la prise de poids sous traitement antirétroviral chez des patients vivant avec le VIH : étude de marqueurs socio-cliniques, inflammatoires et métaboliques. Med Mal Infect 2020. [DOI: 10.1016/j.medmal.2020.06.434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
20
|
Broocks G, Flottmann F, Schönfeld M, Bechstein M, Aye P, Kniep H, Faizy TD, McDonough R, Schön G, Deb-Chatterji M, Thomalla G, Sporns P, Fiehler J, Hanning U, Kemmling A, Meyer L. Incomplete or failed thrombectomy in acute stroke patients with Alberta Stroke Program Early Computed Tomography Score 0-5 - how harmful is trying? Eur J Neurol 2020; 27:2031-2035. [PMID: 32449311 DOI: 10.1111/ene.14358] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2020] [Accepted: 05/18/2020] [Indexed: 10/24/2022]
Abstract
BACKGROUND AND PURPOSE It is currently unknown whether mechanical thrombectomy (MT) for ischaemic stroke patients with low initial Alberta Stroke Program Early Computed Tomography Score (ASPECTS) is clinically beneficial or even harmful. The purpose of this study was to investigate whether failed or incomplete MT in acute large vessel occlusion stroke with an initial ASPECTS ≤ 5 is associated with worse clinical outcome compared to patients not undergoing MT. METHODS This observational cohort study included a consecutive sample of patients with anterior circulation stroke and initial ASPECTS ≤ 5 admitted between March 2015 and August 2019. Failed recanalization was defined as Thrombolysis in Cerebral Infarction (TICI) score 0-2a, and incomplete recanalization as TICI 2b. Clinical outcome was assessed using the modified Rankin Scale (mRS) at 90 days defining very poor clinical outcome as mRS > 4. RESULTS One hundred and seventy patients were included. Ninety-nine patients underwent MT and 71 patients received best medical treatment only. Clinical outcome after failed or incomplete MT (TICI 0-2b) was significantly better compared to patients with medical treatment only (median mRS 5, interquartile range 4-6 vs 5-6, P = 0.03). In multivariable logistic regression analysis, failed or incomplete MT (TICI 0-2b) showed a significantly reduced likelihood for very poor outcome (odds ratio 0.39, 95% confidence interval 0.19-0.83, P = 0.01). Failed MT (TICI 0-2a) was not associated with a worse outcome compared to best medical treatment. CONCLUSIONS Patients with failed or incomplete recanalization results (TICI 0-2b) showed a reduced likelihood for very poor outcome compared with those who did not receive MT. Evidence from randomized trials is needed to confirm that even failed or incomplete MT is not harmful in these patients.
Collapse
Affiliation(s)
- G Broocks
- Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - F Flottmann
- Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - M Schönfeld
- Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - M Bechstein
- Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - P Aye
- Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - H Kniep
- Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - T D Faizy
- Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.,Department of Radiology, Stanford University, Stanford, CA, USA
| | - R McDonough
- Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - G Schön
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - M Deb-Chatterji
- Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - G Thomalla
- Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - P Sporns
- Department of Neuroradiology, Universitätsspital Basel, Basel, Switzerland
| | - J Fiehler
- Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - U Hanning
- Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - A Kemmling
- Department of Neuroradiology, Westpfalz-Klinikum, Kaiserslautern, Germany.,Department of Neuroradiology, University Medical Center Schleswig-Holstein, Lübeck, Germany
| | - L Meyer
- Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
21
|
Bongiorno G, Meyer L, Evans A, Lekouch N, Bianchi R, Khoury C, Chiummo R, Thomas E, Gradoni L. A single oral dose of fluralaner (Bravecto®) in dogs rapidly kills 100% of blood-fed Phlebotomus perniciosus, a main visceral leishmaniasis vector, for at least 1 month after treatment. Med Vet Entomol 2020; 34:240-243. [PMID: 31769060 PMCID: PMC7318609 DOI: 10.1111/mve.12420] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 08/28/2019] [Revised: 10/20/2019] [Accepted: 10/27/2019] [Indexed: 06/10/2023]
Abstract
Dogs are the reservoir host of zoonotic visceral leishmaniasis (VL) caused by Leishmania infantum (Kinetoplastida: Trypanosomatidae). Both subclinically-infected and sick animals can be infectious to competent phlebotomine vectors. The degree and duration of insecticidal efficacy of an oral dose of fluralaner (Bravecto®; Merck Animal Health) was determined in dogs exposed to bites of Phlebotomus perniciosus (Diptera: Psychodidae), a main Mediterranean vector of VL. Twelve dogs allocated to two groups of six animals each were included in a parallel-group designed, negative-controlled, randomized, blinded, single-centre efficacy study. Group 2 was treated with fluralaner on day 0, and sand-fly exposure of both groups was performed on days 1, 28 and 84. Viability of blood-fed females was assessed up to 96 h after exposure and efficacy was measured as the survival rate of specimens fed on Group 2 versus those fed on Group 1. A mortality of 100% was recorded at 24 h in females fed on Group 2 at both days 1 and 28. Significant insecticidal efficacy was still observed on day 84, with > 50% mortality recorded by 48 h post blood meal in Group 2. Fluralaner treatment of dogs represents a promising and affordable method for reducing the pool of infected vectors in endemic settings of zoonotic VL.
Collapse
Affiliation(s)
- G. Bongiorno
- Unit of Vector‐borne DiseasesIstituto Superiore di SanitàRomeItaly
| | - L. Meyer
- Clinvet SA MoroccoMohammediaMorocco
| | - A. Evans
- Clinvet SA MoroccoMohammediaMorocco
| | | | - R. Bianchi
- Unit of Vector‐borne DiseasesIstituto Superiore di SanitàRomeItaly
| | - C. Khoury
- Unit of Vector‐borne DiseasesIstituto Superiore di SanitàRomeItaly
| | - R. Chiummo
- MSD Animal Health Innovation GmbHSchwabenheimGermany
| | - E. Thomas
- MSD Animal Health Innovation GmbHSchwabenheimGermany
| | - L. Gradoni
- Unit of Vector‐borne DiseasesIstituto Superiore di SanitàRomeItaly
| |
Collapse
|
22
|
Couffignal C, Kolta S, Flamant M, Cazanave C, Haymann JP, Mentré F, Duval X, Leport C, Raffi F, Chêne G, Salamon R, Moatti JP, Pierret J, Spire B, Brun-Vézinet F, Fleury H, Masquelier B, Peytavin G, Garraffo R, Costagliola D, Dellamonica P, Katlama C, Meyer L, Salmon D, Sobel A, Cuzin L, Dupon M, Le Moing V, Marchou B, May T, Morlat P, Rabaud C, Waldner-Combernoux A, Hardel L, Reboud P, Couffin-Cadiergues S, Marchand L, Assuied A, Carrieri P, Habak S, Couturier F, Jadand C, Perrier A, Préau M, Protopopescu C, Schmit J, Chennebault J, Faller J, Magy-Bertrand N, Chirouze C, Humbert P, Longy-Boursier, Neau D, Granier P, Ansart S, Verdon R, Merrien D, Chevojon P, Sobel A, Levy Y, Piroth L, Perronne C, Froguel E, Ceccaldi J, Chidiac C, Grégoire V, Reynes J, Fuzibet JG, Arsac P, Bouvet E, Bricaire F, Monsonego J, Girard P, Guillevin L, Herson S, Molina J, Pialoux G, Sain O, Sellier P, Roblot F, Bani-Sadr F, Michelet C, Lucht F, Debord C, Martin T, De Jaureguiberry J, Bernard L. Nevirapine Use Is Associated with Higher Bone Mineral Density in HIV-1 Positive Subjects on Long-Term Antiretroviral Therapy. AIDS Res Hum Retroviruses 2020; 36:399-405. [PMID: 31891665 DOI: 10.1089/aid.2019.0229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
We assessed bone mineral density (BMD) in a cohort of human immunodeficiency virus (HIV)-positive patients after a median of 11 years of combination antiretroviral therapy (cART) and evaluated the respective role of HIV infection and antiretroviral drugs (ARVs). A cross-sectional study of 162 participants (131 male) from the ANRS-C08 cohort was performed with bone dual-energy X-ray absorptiometry (DXA) scans and renal assessment. The window of exposure to ARVs was defined as an exposure of more than six cumulative months during the last 3 years before the DXA evaluation to account for a cumulative exposure that could affect bone remodeling. The association with low BMD (Z-score < -2) was assessed by a multiple logistic regression model. The study population was 50 years (median), hepatitis C virus (HCV) (18%), and hepatitis B virus (HBV) (8%) coinfection with HIV-RNA <50 c/mL in 89%, median CD4 of 619/mm3. Prevalence of low BMD was 18% in males and 6% in females. The factors associated with a Z-score < -2 in males were uric acid renal loss [adjusted odds ratio (aOR): 6.1; 95% confidence interval (CI): 1.2-31.5; p = .03], HCV coinfection (aOR: 4.0; 95% CI: 1.3-12.2; p = .02), and less frequent window of exposure to nevirapine (NVP) (aOR: 0.1; 95% CI: 0.02-0.6; p = .01). For the full study sample, there was a strong positive association between duration of exposure to NVP and lumbar spine Z-score (p = .004). HIV-positive patients exposed to long-term cART have a high incidence of low BMD. Tenofovir disoproxil fumarate and ritonavir-boosted protease inhibitors did not seem to be associated with increased risk of low BMD, whereas NVP exposure appeared to have an independent positive association.
Collapse
Affiliation(s)
- Camille Couffignal
- Infection, Antimicrobials, Modeling, Evolution (IAME) UMR 1137, INSERM and Université of Paris, Paris, France
| | - Sami Kolta
- Department of Rheumatology, University Hospital Cochin, Assistance Publique–Hôpitaux de Paris, INSERM UMR-1153, Paris, France
| | - Martin Flamant
- Department of Physiology, University Hospital Bichat, Assistance Publique–Hôpitaux de Paris, Paris, France
| | - Charles Cazanave
- Infectious Diseases Department, University Hospital Bordeaux, Bordeaux, France
| | - Jean-Philippe Haymann
- Department of Physiology, University Hospital Tenon, and INSERM UMR_S1155, Paris, France
| | - France Mentré
- Infection, Antimicrobials, Modeling, Evolution (IAME) UMR 1137, INSERM and Université of Paris, Paris, France
| | - Xavier Duval
- Infection, Antimicrobials, Modeling, Evolution (IAME) UMR 1137, INSERM and Université of Paris, Paris, and INSERM CIC1425, Paris, France
| | - Catherine Leport
- Unité COREB (Coordination du Risque Epidémique et Biologique), Assistance Publique–Hôpitaux de Paris, Paris, France
| | - François Raffi
- Infectious Diseases Department, University Hospital Hotel-Dieu, and INSERM CIC 1413, University of Nantes, Nantes, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Marcellin F, Di Beo V, Aumaitre H, Mora M, Wittkop L, Duvivier C, Protopopescu C, Lacombe K, Esterle L, Berenger C, Gilbert C, Bouchaud O, Poizot-Martin I, Sogni P, Salmon-Ceron D, Carrieri P, Wittkop L, Sogni P, Esterle L, Trimoulet P, Izopet J, Serfaty L, Paradis V, Spire B, Carrieri P, Valantin M, Pialoux G, Chas J, Poizot-Martin I, Barange K, Naqvi A, Rosenthal E, Bicart-See A, Bouchaud O, Gervais A, Lascoux-Combe C, Goujard C, Lacombe K, Duvivier C, Neau D, Morlat P, Bani-Sadr F, Meyer L, Boufassa F, Autran B, Roque A, Solas C, Fontaine H, Costagliola D, Piroth L, Simon A, Zucman D, Boué F, Miailhes P, Billaud E, Aumaître H, Rey D, Peytavin G, Petrov-Sanchez V, Lebrasseur-Longuet D, Salmon D, Usubillaga R, Sogni P, Terris B, Tremeaux P, Katlama C, Valantin M, Stitou H, Simon A, Cacoub P, Nafissa S, Benhamou Y, Charlotte F, Fourati S, Poizot-Martin I, Zaegel O, Laroche H, Tamalet C, Pialoux G, Chas J, Callard P, Bendjaballah F, Amiel C, Le Pendeven C, Marchou B, Alric L, Barange K, Metivier S, Selves J, Larroquette F, Rosenthal E, Naqvi A, Rio V, Haudebourg J, Saint-Paul M, De Monte A, Giordanengo V, Partouche C, Bouchaud O, Martin A, Ziol M, Baazia Y, Iwaka-Bande V, Gerber A, Uzan M, Bicart-See A, Garipuy D, Ferro-Collados M, Selves J, Nicot F, Gervais A, Yazdanpanah Y, Adle-Biassette H, Alexandre G, Peytavin G, Lascoux-Combe C, Molina J, Bertheau P, Chaix M, Delaugerre C, Maylin S, Lacombe K, Bottero J, Krause J, Girard P, Wendum D, Cervera P, Adam J, Viala C, Vittecocq D, Goujard C, Quertainmont Y, Teicher E, Pallier C, Lortholary O, Duvivier C, Rouzaud C, Lourenco J, Touam F, Louisin C, Avettand-Fenoel V, Gardiennet E, Mélard A, Neau D, Ochoa A, Blanchard E, Castet-Lafarie S, Cazanave C, Malvy D, Dupon M, Dutronc H, Dauchy F, Lacaze-Buzy L, Desclaux A, Bioulac-Sage P, Trimoulet P, Reigadas S, Morlat P, Lacoste D, Bonnet F, Bernard N, Hessamfar, J M, Paccalin F, Martell C, Pertusa M, Vandenhende M, Mercié P, Malvy D, Pistone T, Receveur M, Méchain M, Duau P, Rivoisy C, Faure I, Caldato S, Bioulac-Sage P, Trimoulet P, Reigadas S, Bellecave P, Tumiotto C, Pellegrin J, Viallard J, Lazzaro E, Greib C, Bioulac-Sage P, Trimoulet P, Reigadas S, Zucman D, Majerholc C, Brollo M, Farfour E, Boué F, Polo Devoto J, Kansau I, Chambrin V, Pignon C, Berroukeche L, Fior R, Martinez V, Abgrall S, Favier M, Deback C, Lévy Y, Dominguez S, Lelièvre J, Lascaux A, Melica G, Billaud E, Raffi F, Allavena C, Reliquet V, Boutoille D, Biron C, Lefebvre M, Hall N, Bouchez S, Rodallec A, Le Guen L, Hemon C, Miailhes P, Peyramond D, Chidiac C, Ader F, Biron F, Boibieux A, Cotte L, Ferry T, Perpoint T, Koffi J, Zoulim F, Bailly F, Lack P, Maynard M, Radenne S, Amiri M, Valour F, Koffi J, Zoulim F, Bailly F, Lack P, Maynard M, Radenne S, Augustin-Normand C, Scholtes C, Le-Thi T, Piroth L, Chavanet P, Duong Van Huyen M, Buisson M, Waldner-Combernoux A, Mahy S, Binois R, Simonet-Lann A, Croisier-Bertin D, Salmon Rousseau A, Martins C, Aumaître H, Galim S, Bani-Sadr F, Lambert D, Nguyen Y, Berger J, Hentzien M, Brodard V, Rey D, Partisani M, Batard M, Cheneau C, Priester M, Bernard-Henry C, de Mautort E, Gantner et S Fafi-Kremer P, Roustant F, Platterier P, Kmiec I, Traore L, Lepuil S, Parlier S, Sicart-Payssan V, Bedel E, Anriamiandrisoa S, Pomes C, Touam F, Louisin C, Mole M, Bolliot C, Catalan P, Mebarki M, Adda-Lievin A, Thilbaut P, Ousidhoum Y, Makhoukhi F, Braik O, Bayoud R, Gatey C, Pietri M, Le Baut V, Ben Rayana R, Bornarel D, Chesnel C, Beniken D, Pauchard M, Akel S, Caldato S, Lions C, Ivanova A, Ritleg AS, Debreux C, Chalal L, Zelie J, Hue H, Soria A, Cavellec M, Breau S, Joulie A, Fisher P, Gohier S, Croisier-Bertin D, Ogoudjobi S, Brochier C, Thoirain-Galvan V, Le Cam M, Carrieri P, Chalouni M, Conte V, Dequae-Merchadou L, Desvallees M, Esterle L, Gilbert C, Gillet S, Knight R, Lemboub T, Marcellin F, Michel L, Mora M, Protopopescu C, Roux P, Spire B, Tezkratt S, Barré T, Baudoin M, Santos M, Di Beo V, Nishimwe M, Wittkop L. Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH). J Hepatol 2020; 72:588-591. [PMID: 31924411 DOI: 10.1016/j.jhep.2019.10.019] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/10/2019] [Revised: 10/17/2019] [Accepted: 10/25/2019] [Indexed: 01/26/2023]
Affiliation(s)
- Fabienne Marcellin
- Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l'Information Médicale, Marseille, France; ORS PACA, Observatoire régional de la santé Provence-Alpes-Côte d'Azur, Marseille, France.
| | - Vincent Di Beo
- Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l'Information Médicale, Marseille, France; ORS PACA, Observatoire régional de la santé Provence-Alpes-Côte d'Azur, Marseille, France
| | - Hugues Aumaitre
- Infectious and Tropical Disease Unit, Perpignan Hospital Center, Perpignan, France
| | - Marion Mora
- Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l'Information Médicale, Marseille, France; ORS PACA, Observatoire régional de la santé Provence-Alpes-Côte d'Azur, Marseille, France
| | - Linda Wittkop
- Univ. Bordeaux, ISPED, Inserm, Bordeaux Population Health Research Center, Team MORPH3EUS, UMR 1219, CIC-EC 1401, F-33000 Bordeaux, France; CHU de Bordeaux, Pole de santé publique, F-33000 Bordeaux, France
| | - Claudine Duvivier
- AP-HP-Necker Hospital, Infectious Diseases Department, Necker-Pasteur Infectiology Center, IHU Imagine, Université de Paris, INSERM, U1016, Institut Cochin, CNRS, UMR8104, Paris, France; Institut Pasteur, Medical Center of Institut Pasteur, Necker-Pasteur Infectiology Center, Paris, France
| | - Camelia Protopopescu
- Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l'Information Médicale, Marseille, France; ORS PACA, Observatoire régional de la santé Provence-Alpes-Côte d'Azur, Marseille, France
| | - Karine Lacombe
- Infectious and Tropical Disease Unit, Paris Public Hospitals, Saint-Antoine Hospital, Paris, France; UMR S1136, Pierre Louis Epidemiology and Public Health Institute, Pierre and Marie Curie University, Paris, France
| | - Laure Esterle
- Univ. Bordeaux, ISPED, Inserm, Bordeaux Population Health Research Center, Team MORPH3EUS, UMR 1219, CIC-EC 1401, F-33000 Bordeaux, France
| | - Cyril Berenger
- Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l'Information Médicale, Marseille, France; ORS PACA, Observatoire régional de la santé Provence-Alpes-Côte d'Azur, Marseille, France
| | - Camille Gilbert
- Univ. Bordeaux, ISPED, Inserm, Bordeaux Population Health Research Center, Team MORPH3EUS, UMR 1219, CIC-EC 1401, F-33000 Bordeaux, France
| | - Olivier Bouchaud
- Infectious and Tropical Disease Unit, Paris Publics Hospitals, Avicenne Hospital, Bobigny, France; Paris 13 Nord University, Bobigny, France
| | - Isabelle Poizot-Martin
- Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l'Information Médicale, Marseille, France; APHM Sainte-Marguerite, Clinical Immunohematology Unit, Aix Marseille University, Marseille, France
| | - Philippe Sogni
- Université Paris Descartes, Paris, France; INSERM U-1223, Institut Pasteur, Paris, France; Service d'Hépatologie, hôpital Cochin, Assistance Publique - Hôpitaux de Paris, France
| | - Dominique Salmon-Ceron
- Université Paris Descartes, Paris, France; Service Maladies infectieuses et tropicales, AP-HP, Hôpital Cochin, Paris, France
| | - Patrizia Carrieri
- Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l'Information Médicale, Marseille, France; ORS PACA, Observatoire régional de la santé Provence-Alpes-Côte d'Azur, Marseille, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Gallagher AJ, Meyer L, Pethybridge HR, Huveneers C, Butcher PA. Effects of short-term capture on the physiology of white sharks Carcharodon carcharias: amino acids and fatty acids. ENDANGER SPECIES RES 2019. [DOI: 10.3354/esr00997] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
25
|
Waegell A, Dormegny L, Meyer L, Olteanu S, Lenoble P. Anatomical and functional outcomes of ILM interposition in surgery for large macular holes: A retrospective study. J Fr Ophtalmol 2019; 42:951-958. [PMID: 31248610 DOI: 10.1016/j.jfo.2019.05.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2019] [Revised: 04/23/2019] [Accepted: 05/20/2019] [Indexed: 11/18/2022]
Abstract
INTRODUCTION While surgery for small macular holes (<400μm) is well-described, the results are not as clear-cut for larger holes (>400μm). Our purpose is to demonstrate the difference in terms of closure and final visual acuity between 3 techniques: the classical technique, the FLAP technique and internal limiting membrane (ILM) transfer. METHODS This retrospective non-randomized study included consecutive patients with a macular hole greater than 400μm. Myopic eyes (>26.5mm or >6.50D) and eyes with other retinal comorbidities were excluded. All patients underwent pars plana vitrectomy in combination with one of the 3 techniques. RESULTS We included 84 eyes of 77 patients between 2005 and 2018; 57 in the classic group (A), 13 in the FLAP group (B) and 14 in the ILM transfer group (C). The closure rate at 3 months was 70.18 % in group A, 100 % in group B and 92.86 % in group C. The closure rate was significantly higher in group B and C compared to group A. There was no significant improvement between pre- and post-operative best corrected visual acuity in any group. The gain in BCVA was 2.90 lines (±2.98) in group A, 3.40 lines (±2.40) in group B, and 1.07 lines (±1.04) in group C. The gain was significantly lower in group C compared to group A and B. CONCLUSION ILM interposition appears to offer a true anatomical advantage for closing large holes, but the functional recovery does not appear to be better or worse.
Collapse
Affiliation(s)
- A Waegell
- Louis Pasteur University, 67000 Strasbourg, France.
| | - L Dormegny
- Louis Pasteur University, 67000 Strasbourg, France
| | - L Meyer
- Pasteur Hospital, 68000 Colmar, France
| | - S Olteanu
- Pasteur Hospital, 68000 Colmar, France
| | - P Lenoble
- Pasteur Hospital, 68000 Colmar, France
| |
Collapse
|
26
|
Wang X, Shi Q, Chen T, Cleeland C, Gonzalez AG, Ramirez P, Iniesta-Donate M, Meyer L. Measuring functional impairment status with objective and subjective methods for perioperative care post gynecological surgery. Clin Nutr ESPEN 2019. [DOI: 10.1016/j.clnesp.2019.03.029] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
27
|
Andres E, Meyer L, Talha S, Hajjam A, Hajjam M, Jeandidier N. Télésurveillance du patient diabétique de type 2 et/ou insuffisant cardiaque : l’expérience Strasbourgeoise. Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.03.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
28
|
Avettand-Fénoël V, Mélard A, Gueudin M, Maillard A, Dina J, Gousset M, Chaix ML, Lerolle N, Viard JP, Meyer L, Plantier JC, Rouzioux C. Comparative performance of the Biocentric Generic Viral Load, Roche CAP/CTM v1.5, Roche CAP/CTM v2.0 and m2000 Abbott assays for quantifying HIV-1 B and non-B strains: Underestimation of some CRF02 strains. J Clin Virol 2018; 110:36-41. [PMID: 30530097 DOI: 10.1016/j.jcv.2018.12.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2018] [Revised: 11/26/2018] [Accepted: 12/02/2018] [Indexed: 12/29/2022]
Abstract
BACKGROUND HIV-1 viral load testing is now recommended by the World Health Organization for every patient receiving antiretroviral therapy (ART). OBJECTIVES The objective of this study is to evaluate the performance of commercial assays for their ability to quantify HIV-1 strains currently circulating in France. STUDY DESIGN The performances of the Generic HIV-RNA assay from Biocentric were compared to those of the Roche CAP/CTM v1.5, Roche CAP/CTM v2.0 and Abbott m2000 RealTime HIV-1 assays. A total of 1885 HIV-1 plasma samples were tested, including 684 samples from patients included in the ANRS-Primo Cohort. RESULTS We found a good concordance of quantification between the Roche v2.0 and the Biocentric assays, both of which were superior to the Roche v1.5 assay. We show moderate agreement between techniques; however, CRF02_AG strains and undetermined viruses were underestimated when quantified with the Roche CAP/CTM v2.0. In contrast, a comparison of the Biocentric and Abbott assay results showed strong agreement between assays, indicating that both are well suited for quantification of CRF02_AG strains. Moreover, a 2% underestimation of the B subtypes was observed with the Biocentric assay. CONCLUSIONS These results have implications for viral load monitoring in Western Africa, where CRF02_AG strains are highly prevalent. Closer epidemiological surveillance and evaluation of commercial assays are still necessary to better evaluate the impact of the genetic evolution of circulating viruses on HIV-RNA quantification in the regions most affected by the HIV-1 epidemic.
Collapse
Affiliation(s)
- V Avettand-Fénoël
- Université Paris Descartes, EA 7327, Sorbonne Paris Cité, AP-HP, Laboratoire de Virologie, Hôpital Necker, Paris, France
| | - A Mélard
- Université Paris Descartes, EA 7327, Sorbonne Paris Cité, AP-HP, Laboratoire de Virologie, Hôpital Necker, Paris, France
| | - M Gueudin
- Normandie Université, UNIROUEN, EA2656 GRAM, CHU de Rouen, Laboratoire de virologie, F-76000, Rouen, France
| | - A Maillard
- Laboratoire de Virologie, Hôpital de Rennes, Rennes, France
| | - J Dina
- Université de Normandie, EA 2556, Hôpital de Caen, département de Virologie, Caen, France
| | - M Gousset
- Université Paris Descartes, EA 7327, Sorbonne Paris Cité, AP-HP, Laboratoire de Virologie, Hôpital Necker, Paris, France
| | - M L Chaix
- INSERM UMR 942 Université Paris Diderot, Laboratoire de Virologie, APHP Hôpital Saint-Louis, Paris, France
| | - N Lerolle
- INSERM CESP U1018, Université Paris Sud, Le Kremlin Bicêtre, France
| | - J P Viard
- Université Paris Descartes, EA 7327, Sorbonne Paris Cité, AP-HP, Centre de Diagnostic et de Thérapeutique, Hôpital Hôtel Dieu, France
| | - L Meyer
- INSERM CESP U1018, Université Paris Sud, Le Kremlin Bicêtre, France
| | - J C Plantier
- Normandie Université, UNIROUEN, EA2656 GRAM, CHU de Rouen, Laboratoire de virologie, F-76000, Rouen, France
| | - C Rouzioux
- Université Paris Descartes, EA 7327, Sorbonne Paris Cité, AP-HP, Laboratoire de Virologie, Hôpital Necker, Paris, France.
| | | |
Collapse
|
29
|
Thomas L, Ilic J, Fontaa V, Luca F, Meyer L, Rohr S, Pradignac A. Évolution des traits de la personnalité chez des patients obèses après chirurgie bariatrique et conséquences sur les variations pondérales postopératoires. NUTR CLIN METAB 2018. [DOI: 10.1016/j.nupar.2018.09.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
30
|
Dormegny L, Simonis JS, Meyer L, Lenoble P. [Focal choroidal excavation: Three-year follow-up of an isolated case]. J Fr Ophtalmol 2018; 41:e417-e419. [PMID: 30348600 DOI: 10.1016/j.jfo.2018.03.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2017] [Revised: 11/18/2017] [Accepted: 03/13/2018] [Indexed: 10/28/2022]
Affiliation(s)
- L Dormegny
- Service d'ophtalmologie, hôpitaux civils de Colmar, 68024 Colmar, France.
| | - J-S Simonis
- Service d'ophtalmologie, hôpitaux civils de Colmar, 68024 Colmar, France
| | - L Meyer
- Service d'ophtalmologie, hôpitaux civils de Colmar, 68024 Colmar, France
| | - P Lenoble
- Service d'ophtalmologie, hôpitaux civils de Colmar, 68024 Colmar, France
| |
Collapse
|
31
|
Van Aken CME, Meyer L, Lohner L, Anders S, Püschel K, Schmalfeldt B, Witzel I. Auftreten genitaler Verletzungen bei Frauen nach Sexualdelikten – unizentrische Analyse zur Bedeutung der gynäkologischen Untersuchungen. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- CME Van Aken
- Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie, Hamburg, Deutschland
| | - L Meyer
- Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie, Hamburg, Deutschland
| | - L Lohner
- Universitätsklinikum Hamburg-Eppendorf, Institut für Rechtsmedizin, Hamburg, Deutschland
| | - S Anders
- Universitätsklinikum Hamburg-Eppendorf, Institut für Rechtsmedizin, Hamburg, Deutschland
| | - K Püschel
- Universitätsklinikum Hamburg-Eppendorf, Institut für Rechtsmedizin, Hamburg, Deutschland
| | - B Schmalfeldt
- Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie, Hamburg, Deutschland
| | - I Witzel
- Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie, Hamburg, Deutschland
| |
Collapse
|
32
|
Ravanat C, Freund M, Schuhler S, Grunert P, Meyer L, Cazenave JP. Species Specific Immunoassays to Measure Blood Platelet and Coagulation Activation in the Rat. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1650711] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryThe purpose of this study was to develop specific and sensitive immunoassays to detect early indices of hypercoagulability in the rat. Rat platelet factor 4 (rPF4) and rat fibrinopeptide A (rFPA) assays, tools for the detection of activation of platelets and coagulation respectively, were designed using antibodies raised against purified rPF4 and against synthetic rFPA. The relevance of these new assays and of the commercially available ELISA kit for thrombin-antithrombin III (TAT) complexes was demonstrated in a rat model of a prethrombotic state induced by intravenous infusion of varying doses of thromboplastin (90 to 2400 μl/kg/h). In this model, the immunoassays allowed simultaneous detection of low levels of rFPA and rPF4 which were correlated with fibrinogen and platelet consumption and TAT generation and further proved to be of higher sensitivity than the classical methods of platelet count or measurement of fibrinogen levels. Plasma concentrations of rFPA, rPF4 and TAT were dependent on infusion time and thromboplastin dose, while hirudin (1 mg/kg) prevented their appearance. Thus the new specific immunoassays for rPF4 and rFPA and the commercial human TAT assay represent useful tools for pathophysiological studies or the screening of antithrombotic drugs in rats.
Collapse
Affiliation(s)
- C Ravanat
- NSERM U.311, Etablissement de Transfusion Sanguine de Strasbourg, Strasbourg
| | - M Freund
- NSERM U.311, Etablissement de Transfusion Sanguine de Strasbourg, Strasbourg
- Laboratoire Centeon, Lingolsheim, France
| | - S Schuhler
- NSERM U.311, Etablissement de Transfusion Sanguine de Strasbourg, Strasbourg
| | - P Grunert
- NSERM U.311, Etablissement de Transfusion Sanguine de Strasbourg, Strasbourg
| | - L Meyer
- Laboratoire Centeon, Lingolsheim, France
| | - J-P Cazenave
- NSERM U.311, Etablissement de Transfusion Sanguine de Strasbourg, Strasbourg
| |
Collapse
|
33
|
Spratt J, Mattison L, Kerns N, Huddleston S, Meyer L, Loor G, Iaizzo P. Prolonged Preservation and Evaluation of Human Lungs With Portable Normothermic EVLP. J Heart Lung Transplant 2018. [DOI: 10.1016/j.healun.2018.01.1300] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
34
|
Taleb O, Patte-Mensah C, Meyer L, Kemmel V, Geoffroy P, Miesch M, Mensah-Nyagan AG. Evidence for effective structure-based neuromodulatory effects of new analogues of neurosteroid allopregnanolone. J Neuroendocrinol 2018; 30. [PMID: 29265686 DOI: 10.1111/jne.12568] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/15/2017] [Revised: 11/22/2017] [Accepted: 12/12/2017] [Indexed: 02/06/2023]
Abstract
The neurosteroid allopregnanolone (AP) modulates neuroendocrine/neurobiological processes, including hypothalamic-pituitary-adrenocortical activities, pain, anxiety, neurogenesis and neuroprotection. These observations raised the hope of developing AP-based therapies against neuroendocrine and/or neurodegenerative disorders. However, the pleiotropic actions of AP, particularly its cell-proliferation-promoting effects, hamper the development of selective/targeted therapies. For example, although AP-induced neurogenesis may serve to compensate neuronal loss in degenerative brains, AP-evoked cell-proliferation is contraindicated for steroid-sensitive cancer patients. To foster progress, we synthesised 4 novel AP analogues of neurosteroids (ANS) designated BR053 (12-oxo-epi-AP), BR297 (O-allyl-epi-AP), BR351 (O-allyl-AP) and BR338 (12-oxo-AP). First, because AP is well-known as allosteric modulator of GABAA receptors (GABAA-R), we used the electrophysiological patch-clamp technique to determine the structure-activity relationship of our ANS on GABAA-activated current in NCB20 cells expressing functional GABAA-R. We found that the addition of 12-oxo-group did not significantly change the respective positive or negative allosteric effects of 3α-AP or 3β-(epi)-AP analogues. Importantly, substitution of the 3α-hydroxyl-group by 3α-O-allyl highly modified the ANS activities. Unlike AP, BR351 induced a long-lasting desensitisation/inhibition of GABAA-R. Interestingly, replacement of the 3β-hydroxyl by 3β-O-allyl (BR297) completely reversed the activity from negative to positive allosteric action. In a second step, we compared the actions of AP and ANS on SH-SY5Y neuronal cell viability/proliferation using MTT-reduction assays. Different dose-response curves were demonstrated for AP and the ANS. By contrast to AP, BR297 was totally devoid of cell-proliferative effect. Finally, we compared AP and ANS abilities to protect against oxidative stress-induced neuronal death pivotally involved in neurodegenerative diseases. Both BR351 and BR297 had notable advantages over AP in protecting SH-SY5Y cells against oxidative stress-induced death. Thus, BR297 appears to be a potent neuroprotective compound devoid of cell-proliferative activity. Altogether, our results suggest promising perspectives for the development of neurosteroid-based selective and effective strategies against neuroendocrine and/or neurodegenerative disorders.
Collapse
Affiliation(s)
- O Taleb
- Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques, INSERM U1119, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France
| | - C Patte-Mensah
- Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques, INSERM U1119, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France
| | - L Meyer
- Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques, INSERM U1119, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France
| | - V Kemmel
- Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques, INSERM U1119, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France
| | - P Geoffroy
- Laboratoire de Chimie Organique Synthétique, UMR 7177, Institut de Chimie de l'Université de Strasbourg, Strasbourg, France
| | - M Miesch
- Laboratoire de Chimie Organique Synthétique, UMR 7177, Institut de Chimie de l'Université de Strasbourg, Strasbourg, France
| | - A-G Mensah-Nyagan
- Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques, INSERM U1119, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France
| |
Collapse
|
35
|
Seng R, Mutuon P, Riou J, Duvivier C, Weiss L, Lelievre JD, Meyer L, Vittecoq D, Zak Dit Zbar O, Frenkiel J, Frank-Soltysiak M, Boue F, Rapp C, Sobel A, Brucker G, Goujard C, Salmon D. Hospitalization of HIV positive patients: Significant demand affecting all hospital sectors. Rev Epidemiol Sante Publique 2017; 66:7-17. [PMID: 29233572 DOI: 10.1016/j.respe.2017.08.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2016] [Revised: 06/16/2017] [Accepted: 08/30/2017] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND In a context of the evolution of severe morbidities in patients living with HIV (PLWH), the aim of this study was to describe reasons for hospitalization and the mode of care for the patients requiring hospitalization. METHODS All admissions (≥24h) of PLWH to 10 hospitals in the south of Paris (COREVIH Ile-de-France Sud) between 1/1/2011 and 12/31/2011 were identified. The hospital database and the file of patients followed in the HIV referral department of each hospital were matched. Detailed clinical and biological data were collected, by returning to the individual medical records, for a random sample (65% of hospitalized patients). RESULTS A total of 3013 hospitalizations (1489 patients) were recorded in 2011. The estimated rate of hospitalized patients was about 8% among the 10105 PLWH routinely managed in COREVIH Ile-de-France Sud in 2011. The majority (58.5%) of these hospitalizations occurred in a unit other than the HIV referral unit. Non-AIDS-defining infections were the main reason for admission (16.4%), followed by HIV-related diseases (15.6%), hepatic/gastrointestinal diseases (12.0%), and cardiovascular diseases (10.3%). The median length of stay was 5 days overall (IQR: 2-11), it was longer among patients admitted to a referral HIV care unit than to another ward. HIV infection had been diagnosed >10 years previously in 61.4% of these hospitalized patients. They often had associated comorbidities (coinfection HCV/HVB 40.5%, smoking 45.8%; hypertension 33.4%, dyslipidemia 28.8%, diabetes 14.8%). Subjects over 60 years old accounted for 15% of hospitalized patients, most of them were virologically controlled under HIV treatment, and cardiovascular diseases were their leading reason for admission. CONCLUSION Needs for hospitalization among PLWH remain important, with a wide variety in causes of admission, involving all hospital departments. It is essential to prevent comorbidities to reduce these hospitalizations, and to maintain a link between the management of PLWH, that becomes rightly, increasing ambulatory, and recourse to specialized inpatient services.
Collapse
Affiliation(s)
- R Seng
- CESP INSERM, Paris-Sud-University, 94276 Le-Kremlin-Bicêtre cedex, France; Department of Epidemiology and Public Health, AP-HP Bicetre hospital, 94276 Le-Kremlin-Bicêtre cedex, France.
| | - P Mutuon
- Department of Epidemiology and Public Health, AP-HP Bicetre hospital, 94276 Le-Kremlin-Bicêtre cedex, France
| | - J Riou
- Department of Epidemiology and Public Health, AP-HP Bicetre hospital, 94276 Le-Kremlin-Bicêtre cedex, France
| | - C Duvivier
- Paris-Descartes University, Sorbonne-Paris-Cité, 75006 Paris, France; Department of Infectious Diseases, Necker-Pasteur Infectious Diseases Center, AP-HP Necker hospital, 75015 Paris, France
| | - L Weiss
- Paris-Descartes University, Sorbonne-Paris-Cité, 75006 Paris, France; Department of Clinical Immunology, AP-HP Georges-Pompidou hospital, 75015 Paris, France
| | - J D Lelievre
- Department of Clinical Immunology and Infectious Diseases, AP-HP Henri-Mondor hospital, 94010 Creteil, France
| | - L Meyer
- CESP INSERM, Paris-Sud-University, 94276 Le-Kremlin-Bicêtre cedex, France; Department of Epidemiology and Public Health, AP-HP Bicetre hospital, 94276 Le-Kremlin-Bicêtre cedex, France
| | - D Vittecoq
- Department of Infectious and Tropical Diseases, AP-HP Bicetre hospital, 94276 Le-Kremlin-Bicêtre cedex, France
| | - O Zak Dit Zbar
- Department of Infectious Diseases, Cognacq-Jay hospital, 75015 Paris, France
| | - J Frenkiel
- Unité d'information médicale, AP-HP Cochin hospital, 75014 Paris, France
| | - M Frank-Soltysiak
- Department of Epidemiology and Public Health, AP-HP Bicetre hospital, 94276 Le-Kremlin-Bicêtre cedex, France
| | - F Boue
- Department of Internal Medicine, AP-HP Antoine-Beclere hospital, 92140 Clamart, France
| | - C Rapp
- Department of Infectious and Tropical Diseases, Hopital d'Instruction des Armées Bégin, 94160 Saint-Mandé, France
| | - A Sobel
- Department of Infectious Diseases and Immunology, AP-HP Hotel-Dieu hospital, 75004 Paris, France
| | - G Brucker
- Department of Epidemiology and Public Health, AP-HP Bicetre hospital, 94276 Le-Kremlin-Bicêtre cedex, France
| | - C Goujard
- CESP INSERM, Paris-Sud-University, 94276 Le-Kremlin-Bicêtre cedex, France; Department of Internal Medicine, AP-HP Bicetre hospital, 94276 Le Kremlin-Bicêtre cedex, France
| | - D Salmon
- Paris-Descartes University, Sorbonne-Paris-Cité, 75006 Paris, France; Department of Internal Medicine and Infectious Diseases, Diagnosis Center, AP-HP Hotel Dieu hospital, 75004 Paris, France
| | | |
Collapse
|
36
|
Meyer L, Massuyeau M, Canel C, Bahougne T, Assemi P, Perrin AE, Wurtz E, Renaud-Picard B, Iamandi C, Kessler R, Kessler L. Association of sleep apnoea syndrome and autonomic neuropathy in type 1 diabetes. Diabetes Metab 2017; 45:206-209. [PMID: 29169926 DOI: 10.1016/j.diabet.2017.10.011] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/19/2017] [Revised: 10/22/2017] [Accepted: 10/23/2017] [Indexed: 11/27/2022]
Affiliation(s)
- L Meyer
- Endocrinology, hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, Bas-Rhin, 67091 Strasbourg, France.
| | - M Massuyeau
- Endocrinology, hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, Bas-Rhin, 67091 Strasbourg, France
| | - C Canel
- Endocrinology, hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, Bas-Rhin, 67091 Strasbourg, France
| | - T Bahougne
- Endocrinology, hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, Bas-Rhin, 67091 Strasbourg, France
| | - P Assemi
- Centre hospitalier de Saverne, 67700 Saverne, France
| | - A-E Perrin
- Centre hospitalier de Saverne, 67700 Saverne, France
| | - E Wurtz
- Centre hospitalier de Saverne, 67700 Saverne, France
| | - B Renaud-Picard
- Endocrinology, hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, Bas-Rhin, 67091 Strasbourg, France
| | - C Iamandi
- Centre hospitalier de Mulhouse, 68100 Mulhouse, France
| | - R Kessler
- Endocrinology, hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, Bas-Rhin, 67091 Strasbourg, France
| | - L Kessler
- Endocrinology, hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, Bas-Rhin, 67091 Strasbourg, France
| |
Collapse
|
37
|
Kuhnke P, Meyer L, Friederici A, Hartwigsen G. P 19 Left posterior inferior frontal gyrus is causally involved in complex sentence comprehension. Clin Neurophysiol 2017. [DOI: 10.1016/j.clinph.2017.06.098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
38
|
Neumann A, Meyer L, Hörster L, Dührsen U, Jöckel KH, Baum J, Merkel-Jens A, Lehmann N, Lax H, Wasem J. Analyse des Ressourcenverbrauchs und der Kosten in der Nachsorge von Blutkrebspatienten. Das Gesundheitswesen 2017. [DOI: 10.1055/s-0037-1605722] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- A Neumann
- Universität Duisburg-Essen, Lehrstuhl für Medizinmanagement, Essen
| | - L Meyer
- Universität Duisburg-Essen, Lehrstuhl für Medizinmanagement, Essen
| | - L Hörster
- Universität Duisburg-Essen, Lehrstuhl für Medizinmanagement, Essen
| | - U Dührsen
- Universitätsklinikum Essen, Klinik für Hämatologie, Essen
| | - KH Jöckel
- Universitätsklinikum Essen, Institut für Medizinische Informatik, Biometrie und Epidemiologie, Essen
| | - J Baum
- Universitätsklinikum Essen, Klinik für Hämatologie, Essen
| | - A Merkel-Jens
- Universitätsklinikum Essen, Institut für Medizinische Informatik, Biometrie und Epidemiologie, Essen
| | - N Lehmann
- Universitätsklinikum Essen, Institut für Medizinische Informatik, Biometrie und Epidemiologie, Essen
| | - H Lax
- Universitätsklinikum Essen, Institut für Medizinische Informatik, Biometrie und Epidemiologie, Essen
| | - J Wasem
- Universität Duisburg-Essen, Lehrstuhl für Medizinmanagement, Essen
| |
Collapse
|
39
|
Canoui E, Lécuroux C, Avettand-Fenoël V, Gousset M, Saez-Cirion A, Meyer L, Boufassa F, Lambotte O, Noel N. Patients « HIV controllers » à charge virale toujours strictement indétectable : un sous-groupe de patients caractérisés par des niveaux bas de réservoirs VIH et des réponses immunitaires faibles. Med Mal Infect 2017. [DOI: 10.1016/j.medmal.2017.03.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
40
|
Rachas A, Tuppin P, de la Rochebrochard E, Faye A, Meyer L, Warszawski J. Hospitalisations et mortalité des jeunes vivant avec une pathologie chronique en France : analyse à partir de l’échantillon généraliste des bénéficiaires. Rev Epidemiol Sante Publique 2017. [DOI: 10.1016/j.respe.2017.01.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
41
|
|
42
|
Taleb O, Bouzobra F, Tekin-Pala H, Meyer L, Mensah-Nyagan AG, Patte-Mensah C. Behavioral and electromyographic assessment of oxaliplatin-induced motor dysfunctions: Evidence for a therapeutic effect of allopregnanolone. Behav Brain Res 2016; 320:440-449. [PMID: 27789344 DOI: 10.1016/j.bbr.2016.10.040] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2016] [Revised: 10/20/2016] [Accepted: 10/23/2016] [Indexed: 12/13/2022]
Abstract
The antineoplastic oxaliplatin (OXAL) is pivotal for metastatic cancer treatments. However, OXAL evokes sensory and motor side-effects including pain, muscle weakness, motor nerve fiber dysfunctions/neuropathies that significantly impact patients' lives. Therefore, preclinical investigations are struggling to characterize effective analgesics against OXAL-induced painful/sensory symptoms but surprisingly, OXAL-evoked motor dysfunctions received little attention although these neurological symptoms are also disabling for patients. Here, we validated a rat model of OXAL-induced motor neuropathy by using (i) behavioral methods as the wire suspension and balance beam tests to assess muscle weakness and (ii) electrophysiological techniques to record the gastrocnemius electromyography (EMG). The conductance velocity of motor fibers was reduced and compound muscle action potential (CMAP) duration increased in OXAL-treated rats, leading to CMAP dispersion with no modification of the area under the curve, reflecting a heterogeneous demyelination of motor fibers. Functional motor unit analysis revealed a 50 % decrease of their estimated number which was compensated by a motor unit size increase. OXAL-induced motor weakness appeared as a combined consequence of motor fiber demyelination and motor axonopathy. Because we previously observed that allopregnanolone (AP) counteracted OXAL-evoked painful/sensory symptoms, we evaluated its action against OXAL-induced motor neurological dysfunctions. AP treatment successfully corrected motor behaviors, conductance velocity, CMAP duration, motor unit number (MUN) and motor unit size altered by OXAL-chemotherapy. These results, which are the first to show that AP efficiently rescues OXAL-induced motor neuropathy, consolidate the idea that AP-based therapy may be relevant for the treatment of both sensory and motor peripheral neuropathies.
Collapse
Affiliation(s)
- O Taleb
- Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques, INSERM U1119, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Bâtiment 3 de la Faculté de Médecine, 11 rue Humann, 67 000 Strasbourg, France
| | - F Bouzobra
- Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques, INSERM U1119, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Bâtiment 3 de la Faculté de Médecine, 11 rue Humann, 67 000 Strasbourg, France
| | - H Tekin-Pala
- Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques, INSERM U1119, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Bâtiment 3 de la Faculté de Médecine, 11 rue Humann, 67 000 Strasbourg, France
| | - L Meyer
- Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques, INSERM U1119, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Bâtiment 3 de la Faculté de Médecine, 11 rue Humann, 67 000 Strasbourg, France
| | - A G Mensah-Nyagan
- Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques, INSERM U1119, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Bâtiment 3 de la Faculté de Médecine, 11 rue Humann, 67 000 Strasbourg, France
| | - C Patte-Mensah
- Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques, INSERM U1119, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Bâtiment 3 de la Faculté de Médecine, 11 rue Humann, 67 000 Strasbourg, France.
| |
Collapse
|
43
|
Meyer L, Hörster L, Dührsen U, Jöckel KH, Baum J, Lehmann N, Merkel-Jens A, Lax H, Wasem J, Neumann A. Analyse des Ressourcenverbrauchs und der Kosten in der Nachsorge von Blutkrebspatienten. Gesundheitswesen 2016. [DOI: 10.1055/s-0036-1586534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
44
|
Wegener A, Meyer L. Update on epidemiological evidence for an association between sun exposure and cataract. Acta Ophthalmol 2016. [DOI: 10.1111/j.1755-3768.2016.0141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
45
|
Bouteloup V, Sabin C, Mocroft A, Gras L, Pantazis N, Le Moing V, d'Arminio Monforte A, Mary-Krause M, Roca B, Miro JM, Battegay M, Brockmeyer N, Berenguer J, Morlat P, Obel N, De Wit S, Fätkenheuer G, Zangerle R, Ghosn J, Pérez-Hoyos S, Campbell M, Prins M, Chêne G, Meyer L, Dorrucci M, Torti C, Thiébaut R. Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients. HIV Med 2016; 18:33-44. [PMID: 27625009 DOI: 10.1111/hiv.12389] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/28/2016] [Indexed: 12/01/2022]
Abstract
OBJECTIVES The aim of this work was to provide a reference for the CD4 T-cell count response in the early months after the initiation of combination antiretroviral therapy (cART) in HIV-1-infected patients. METHODS All patients in the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) cohort who were aged ≥ 18 years and started cART for the first time between 1 January 2005 and 1 January 2010 and who had at least one available measurement of CD4 count and a viral load ≤ 50 HIV-1 RNA copies/mL at 6 months (± 3 months) after cART initiation were included in the study. Unadjusted and adjusted references curves and predictions were obtained using quantile regressions. RESULTS A total of 28 992 patients were included in the study. The median CD4 T-cell count at treatment initiation was 249 [interquartile range (IQR) 150, 336] cells/μL. The median observed CD4 counts at 6, 9 and 12 months were 382 (IQR 256, 515), 402 (IQR 274, 543) and 420 (IQR 293, 565) cells/μL. The two main factors explaining the variation of CD4 count at 6 months were AIDS stage and CD4 count at cART initiation. A CD4 count increase of ≥ 100 cells/mL is generally required in order that patients stay 'on track' (i.e. with a CD4 count at the same percentile as when they started), with slightly higher gains required for those starting with CD4 counts in the higher percentiles. Individual predictions adjusted for factors influencing CD4 count were more precise. CONCLUSIONS Reference curves aid the evaluation of the immune response early after antiretroviral therapy initiation that leads to viral control.
Collapse
Affiliation(s)
- V Bouteloup
- CIC 1401, CHU de Bordeaux, Bordeaux, France.,INSERM U1219 - Centre Inserm Bordeaux Population Health, Université de Bordeaux, Bordeaux, France.,ISPED, Centre INSERM U1219-Bordeaux Population Health, Université de Bordeaux, Bordeaux, France
| | - C Sabin
- Research Department of Infection & Population Health, UCL, London, UK
| | - A Mocroft
- Research Department of Infection & Population Health, UCL, London, UK
| | - L Gras
- Stichting HIV Monitoring, Amsterdam, The Netherlands
| | - N Pantazis
- Department of Hygiene, Epidemiology & Medical Statistics, Athens University Medical School, Athens, Greece
| | - V Le Moing
- Montpellier University, Montpellier, France
| | - A d'Arminio Monforte
- Infectious Diseases Unit, Department of Health Sciences, San Paolo University Hospital, Milan, Italy
| | - M Mary-Krause
- INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), UPMC Univ Paris 06, Sorbonne Universités, F-75013, Paris, France
| | - B Roca
- Hospital General of Castellon, Castellón, Spain
| | - J M Miro
- Infectious Diseases Service. Hospital Clinic - IDIBAPS, University of Barcelona, Barcelona, Spain
| | - M Battegay
- Division of Infectious Diseases and Hospital Epidemiology, Department of Clinical Research, University Hospital of Basel, Basel, Switzerland
| | - N Brockmeyer
- Department of Dermatology, Venerology - Center for Sexual Health and Medicine, Ruhr-Universität Bochum, Bochum, Germany
| | - J Berenguer
- Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - P Morlat
- INSERM U1219 - Centre Inserm Bordeaux Population Health, Université de Bordeaux, Bordeaux, France.,Service de Médecine Interne et Maladies Infectieuses, Hôpital Saint-André, Bordeaux, France
| | - N Obel
- Department of Infectious Diseases, Copenhagen University Hospital, Copenhagen, Denmark
| | - S De Wit
- Department of Infectious Diseases, St Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium
| | - G Fätkenheuer
- Department of Internal Medicine, University of Cologne and German Centre for Infection Research (DZIF), Cologne, Germany
| | - R Zangerle
- Medical University Innsbruck, Innsbruck, Austria
| | - J Ghosn
- APHP, Unité Fonctionnelle de Thérapeutique en Immuno-Infectiologie, Centre Hospitalier Universitaire Hôtel Dieu, Paris, France.,Faculté de Médecine Site Necker, Sorbonne Paris Cité, Université Paris Descartes, EA 7327, Paris, France
| | - S Pérez-Hoyos
- Vall d'Hebrón Institut de Recerca (VHIR), Barcelona, Spain.,Universitat Autònoma de Barcelona, Barcelona, Spain
| | - M Campbell
- CHIP, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - M Prins
- Division of Infectious Diseases, Department of Internal Medicine, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, Amsterdam, The Netherlands.,Department of Infectious Diseases, Public Health Service, Amsterdam, The Netherlands
| | - G Chêne
- CIC 1401, CHU de Bordeaux, Bordeaux, France.,INSERM U1219 - Centre Inserm Bordeaux Population Health, Université de Bordeaux, Bordeaux, France.,ISPED, Centre INSERM U1219-Bordeaux Population Health, Université de Bordeaux, Bordeaux, France.,CHU de Bordeaux, Pole de Sante Publique, Service d'Information Medicale, F-33000, Bordeaux, France
| | - L Meyer
- INSERM, U1018, Epidemiology of HIV, Reproduction, Paediatrics, CESP; University Paris-Sud, Paris, France.,Department of Public Health and Epidemiology, Bicêtre Hospital, AP-HP, Le Kremlin Bicêtre, Paris, France
| | - M Dorrucci
- Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - C Torti
- Unit of Infectious and Tropical Diseases, Department of Medical and Surgical Sciences, University "Magna Graecia", Catanzaro, Italy
| | - R Thiébaut
- INSERM U1219 - Centre Inserm Bordeaux Population Health, Université de Bordeaux, Bordeaux, France.,ISPED, Centre INSERM U1219-Bordeaux Population Health, Université de Bordeaux, Bordeaux, France.,CHU de Bordeaux, Pole de Sante Publique, Service d'Information Medicale, F-33000, Bordeaux, France
| | | |
Collapse
|
46
|
Judd A, Lodwick R, Noguera-Julian A, Gibb DM, Butler K, Costagliola D, Sabin C, van Sighem A, Ledergerber B, Torti C, Mocroft A, Podzamczer D, Dorrucci M, De Wit S, Obel N, Dabis F, Cozzi-Lepri A, García F, Brockmeyer NH, Warszawski J, Gonzalez-Tome MI, Mussini C, Touloumi G, Zangerle R, Ghosn J, Castagna A, Fätkenheuer G, Stephan C, Meyer L, Campbell MA, Chene G, Phillips A. Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe. HIV Med 2016; 18:171-180. [PMID: 27625109 PMCID: PMC5298034 DOI: 10.1111/hiv.12411] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/04/2016] [Indexed: 01/12/2023]
Abstract
Objectives The aim of the study was to determine the time to, and risk factors for, triple‐class virological failure (TCVF) across age groups for children and adolescents with perinatally acquired HIV infection and older adolescents and adults with heterosexually acquired HIV infection. Methods We analysed individual patient data from cohorts in the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). A total of 5972 participants starting antiretroviral therapy (ART) from 1998, aged < 20 years at the start of ART for those with perinatal infection and 15–29 years for those with heterosexual infection, with ART containing at least two nucleoside reverse transcriptase inhibitors (NRTIs) and a nonnucleoside reverse transcriptase inhibitor (NNRTI) or a boosted protease inhibitor (bPI), were followed from ART initiation until the most recent viral load (VL) measurement. Virological failure of a drug was defined as VL > 500 HIV‐1 RNA copies/mL despite ≥ 4 months of use. TCVF was defined as cumulative failure of two NRTIs, an NNRTI and a bPI. Results The median number of weeks between diagnosis and the start of ART was higher in participants with perinatal HIV infection compared with participants with heterosexually acquired HIV infection overall [17 (interquartile range (IQR) 4–111) vs. 8 (IQR 2–38) weeks, respectively], and highest in perinatally infected participants aged 10–14 years [49 (IQR 9–267) weeks]. The cumulative proportion with TCVF 5 years after starting ART was 9.6% [95% confidence interval (CI) 7.0−12.3%] in participants with perinatally acquired infection and 4.7% (95% CI 3.9−5.5%) in participants with heterosexually acquired infection, and highest in perinatally infected participants aged 10–14 years when starting ART (27.7%; 95% CI 13.2−42.1%). Across all participants, significant predictors of TCVF were those with perinatal HIV aged 10–14 years, African origin, pre‐ART AIDS, NNRTI‐based initial regimens, higher pre‐ART viral load and lower pre‐ART CD4. Conclusions The results suggest a beneficial effect of starting ART before adolescence, and starting young people on boosted PIs, to maximize treatment response during this transitional stage of development.
Collapse
Affiliation(s)
- A Judd
- MRC Clinical Trials Unit, University College London, London, UK
| | - R Lodwick
- Department of Infection and Population Health, University College London, London, UK
| | - A Noguera-Julian
- Institut de Recerca Pediàtrica Hospital Sant Joan de Déu, Barcelona, Spain.,Departament de Pediatria, Universitat de Barcelona, Barcelona, Spain.,CIBER de Epidemiología y Salud Pública Ciberesp, Barcelona, Spain
| | - D M Gibb
- MRC Clinical Trials Unit, University College London, London, UK
| | - K Butler
- Department of Infectious Diseases and Immunology, Our Lady's Children's Hospital, Crumlin, Dublin, Ireland
| | - D Costagliola
- INSERM, UPMC Univ Paris 06, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Sorbonne Universités, Paris, France
| | - C Sabin
- Department of Infection and Population Health, University College London, London, UK
| | - A van Sighem
- Stichting HIV Monitoring, Amsterdam, The Netherlands
| | - B Ledergerber
- Division of Infectious Diseases and Hospital Epidemiology, University of Zurich, Zurich, Switzerland
| | - C Torti
- Unit of Infectious and Tropical Diseases, Department of Medical and Surgical Sciences, University "Magna Graecia", Catanzaro, Italy
| | - A Mocroft
- Department of Infection and Population Health, University College London, London, UK
| | - D Podzamczer
- HIV and STD Unit, Infectious Disease Service, Hospital Universitari de Bellvitge. L'Hospitalet, Barcelona, Spain
| | - M Dorrucci
- Istituto Superiore di Sanità, Rome, Italy
| | - S De Wit
- Département of Infectious Diseases, Centre Hospitalier Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium
| | - N Obel
- Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
| | - F Dabis
- INSERM U1219 - Centre Inserm Bordeaux Population Health, Université de Bordeaux, Bordeaux, France.,ISPED, Centre INSERM U1219-Bordeaux Population Health, Université de Bordeaux, Bordeaux, France
| | - A Cozzi-Lepri
- Department of Infection and Population Health, University College London, London, UK
| | - F García
- Clinical Microbiology Department, Complejo Hospitalario Universitario Granada, Instituto de Investigación Biosanitaria ibs.Granada, Granada, Spain
| | - N H Brockmeyer
- Department of Dermatology, Venerology and Allergology, Center for Sexual Health and Medicine, St. Josef Hospital, Ruhr-Universität Bochum, Bochum, Germany
| | - J Warszawski
- INSERM CESP U1018, AP-HP Public Health Department, Université Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre Paris, France
| | - M I Gonzalez-Tome
- HIV and Paeds Infectious Diseases Department, Hospital 12 de Octubre, Madrid, Spain
| | - C Mussini
- Infectious Diseases Clinics, University Hospital, Modena, Italy
| | - G Touloumi
- Department Hygiene, Epidemiology & Medical Statistics, Medical School, National & Kapodistrian University of Athens, Athens, Greece
| | - R Zangerle
- Medical University Innsbruck, Innsbruck, Austria
| | - J Ghosn
- EA 7327, Faculté de Médecine site Necker, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.,APHP, Unité Fonctionnelle de Thérapeutique en Immuno-Infectiologie, Hôpitaux Universitaires Paris Centre site Hôtel Dieu, Paris, France
| | - A Castagna
- San Raffaele Scientific Institute, Vita-SaLute University, Milan, Italy
| | - G Fätkenheuer
- Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
| | - C Stephan
- Second Medical Department, Infectious Diseases Unit, Goethe-University Hospital, Frankfurt, Germany
| | - L Meyer
- INSERM CESP U1018, Université Paris-Sud, Université Paris-Saclay, Paris, France.,AP-HP Public Health Department, Le Kremlin-Bicêtre, Paris, France
| | - M A Campbell
- Centre for Health and Infectious Disease Research, University of Copenhagen, Copenhagen, Denmark
| | - G Chene
- INSERM U1219 - Centre Inserm Bordeaux Population Health, Université de Bordeaux, Bordeaux, France.,ISPED, Centre INSERM U1219-Bordeaux Population Health, Université de Bordeaux, Bordeaux, France.,CHU de Bordeaux, Pole de sante publique, Service d'information medicale, Bordeaux, France
| | - A Phillips
- Department of Infection and Population Health, University College London, London, UK
| | | |
Collapse
|
47
|
Süss D, Drillich M, Klein-Jöbstl D, Wagener K, Krieger S, Thiel A, Meyer L, Schwendenwein I, Iwersen M. Measurement of β-hydroxybutyrate in capillary blood obtained from an ear to detect hyperketonemia in dairy cows by using an electronic handheld device. J Dairy Sci 2016; 99:7362-7369. [DOI: 10.3168/jds.2016-10911] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2016] [Accepted: 05/04/2016] [Indexed: 11/19/2022]
|
48
|
Meyer L, Ulrich M, Ducloux D, Garrigue V, Vigneau C, Boffa J, Clabault K, Mousson C, Nochy D, Vrigneaud L, François H, Valleix S. Caractéristiques génétiques, phénotypiques et évolutives de l’amylose à fibrinogène : une série française. Nephrol Ther 2016. [DOI: 10.1016/j.nephro.2016.07.321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
49
|
Velter A, Sauvage C, Meyer L, Bajos N. Première pénétration anale et usage du préservatif chez les hommes ayant des relations sexuelles avec des hommes : évolution des constructions sociales de l’homosexualité et des normes préventives. Rev Epidemiol Sante Publique 2016. [DOI: 10.1016/j.respe.2016.06.329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
50
|
Bartens MC, Drillich M, Rychli K, Iwersen M, Arnholdt T, Meyer L, Klein-Jöbstl D. Assessment of different methods to estimate bovine colostrum quality on farm. N Z Vet J 2016; 64:263-7. [DOI: 10.1080/00480169.2016.1184109] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- M-C Bartens
- Clinical Unit for Herd Health Management in Ruminants, University Clinic for Ruminants, Department for Farm Animals and Veterinary Public Health, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210 Vienna, Austria
| | - M Drillich
- Clinical Unit for Herd Health Management in Ruminants, University Clinic for Ruminants, Department for Farm Animals and Veterinary Public Health, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210 Vienna, Austria
| | - K Rychli
- Institute of Milk Hygiene, Milk Technology and Food Science, Veterinaerplatz 1, 1210 Vienna, Austria
| | - M Iwersen
- Clinical Unit for Herd Health Management in Ruminants, University Clinic for Ruminants, Department for Farm Animals and Veterinary Public Health, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210 Vienna, Austria
| | - T Arnholdt
- Clinical Unit for Herd Health Management in Ruminants, University Clinic for Ruminants, Department for Farm Animals and Veterinary Public Health, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210 Vienna, Austria
| | - L Meyer
- First Farms A/S, 900 68 Plavecký Štvrtok, Slovakia
| | - D Klein-Jöbstl
- Clinical Unit for Herd Health Management in Ruminants, University Clinic for Ruminants, Department for Farm Animals and Veterinary Public Health, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210 Vienna, Austria
| |
Collapse
|